

BIBLIOGRAPHY: Clinical Retina

1. Adamis A, Shima D, Tolentino M, et al: Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. *Arch Ophthalmol* 1996; 114: 66-71.
2. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high dose supplementation with vitamins C and E, beta-carotene and zinc for age related macular degeneration and visual loss. AREDS report no. 8. *Arch Ophthalmol*. 2001;119:1417-1436.
3. Age-Related Eye Disease Study Research Group. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. *Arch Ophthalmol*. 2003;121:1621-1624.
4. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. *N Engl J Med*. 1994;331:1480-1487.
5. Aiello LP, Pierce EA, Foley ED, et al: Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. *Proc Natl Acad Sci U S A* 1995 Nov 7; 92(23): 10457-61.
6. Algvere PV, Berglin L, Gouras P, et al: Transplantation of RPE in age-related macular degeneration: observations in disciform lesions and dry RPE atrophy. *Graefes Arch Clin Exp Ophthalmol* 1997 Mar; 235(3): 149-58.
7. Algvere PV, Libert C, Lindgarde G, Seregard S: Transpupillary thermotherapy of predominantly occult choroidal neovascularization in age-related macular degeneration with 12 months follow-up. *Acta Ophthalmol Scand* 2003 Apr; 81(2): 110-7.
8. Algvere PV: Clinical possibilities in retinal pigment epithelial transplantations. *Acta Ophthalmol Scand* 1997 Feb; 75(1): 1.
9. Allikmets R, Shroyer NF, Singh N, et al: Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration. *Science* 1997 Sep 19; 277(5333): 1805-7.
10. Allison BA, Waterfield E, Richter AM, Levy JG: The effects of plasma lipoproteins on in vitro tumor cell killing and in vivo tumor photosensitization with benzoporphyrin derivative. *Photochem Photobiol* 1991 Nov; 54(5): 709-15.
11. Amin R, Puklin JE, Frank RN: Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. *Invest Ophthalmol Vis Sci* 1994 Jul; 35(8): 3178-88.
12. Anders N, Stahl H, Dorn A, et al: [Radiotherapy of exudative senile macular degeneration. A prospective controlled study]. *Ophthalmologie* 1998 Nov; 95(11): 760-4.
13. Antioxidant status and neovascular age-related macular degeneration. Eye Disease Case-Control Study Group. *Arch Ophthalmol*. 1993;111:104-109.
14. Antoszyk AN, Gottlieb JL, Machemer R, Hatchell DL. The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization. *Graefes Arch Clin Exp Ophthalmol*. 1993;231:34-40.
15. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. *Arch Ophthalmol*. 1991;109:1109-1114. Erratum in: *Arch Ophthalmol*. 1992;110:761.

BIBLIOGRAPHY: Clinical Retina

16. Arnold JJ, Blinder KJ, Bressler NM, et al. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3. *Am J Ophthalmol*. 2004;137:683-696.
17. Attebo K, Mitchell P, Smith W: Visual acuity and the causes of visual loss in Australia. The Blue Mountains Eye Study. *Ophthalmology* 1996 Mar; 103(3): 357-64.
18. Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. *Ophthalmology*. 2006;113:14-22.
19. Aveline B, Hasan T, Redmond RW: Photophysical and photosensitizing properties of benzoporphyrin derivative monoacid ring A (BPD-MA). *Photochem Photobiol* 1994 Mar; 59(3): 328-35.
20. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. *Ophthalmology*. 2006;113:363-372.
21. Bergink GJ, Hoyng CB, van der Maazen RW, et al: A randomized controlled clinical trial on the efficacy of radiation therapy in the control of subfoveal choroidal neovascularization in age-related macular degeneration: radiation versus observation. *Graefes Arch Clin Exp Ophthalmol* 1998 May; 236(5): 321-5.
22. Bingaman DP, Liu C, Landers R. Local delivery of anecortave acetate inhibits laser-induced choroidal neovascularization (CNV) in the mouse. *Invest Ophthalmol Vis Sci*. 2004;45:S180. 1850/B661.
23. Bird AC, Bressler NM, Bressler SB, et al: An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. *Surv Ophthalmol* 1995 Mar-Apr; 39(5): 367-74.
24. Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3. *Ophthalmology*. Apr 2003;110(4):667-73. .
25. Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donati G, Hao Y. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. *Am J Ophthalmol*. Sep 2003;136(3):407-18. .
26. Bloom SM: Feeder vessel photocoagulation for subfoveal CNV. *Ophthalmology* 1998 Dec; 105(12): 2163-4.
27. Blumenkranz M, Miller J, Guyer D, et al: Preliminary results from a phase II dose-response study of photodynamic therapy with motexafin lutetium to treat subfoveal CNV []. *Invest Ophthalmol Vis Sci* 2000; 41(S531): 2827.
28. Blumenkranz MS, Bressler NM, Bressler SB, et al, for the TAP Study Group: Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5. *Arch Ophthalmol* 2002 Oct; 120(10): 1307-14.

BIBLIOGRAPHY: Clinical Retina

29. Bone RA, Landrum JT, Tarsis SL: Preliminary identification of the human macular pigment. *Vision Res* 1985; 25(11): 1531-5.
30. Borodoker N, Spaide RF, Maranan L, et al. Verteporfin infusion-associated pain. *Am J Ophthalmol*. 2002;133:211-214.
31. Borrillo JL, Martididis A, Federman JL, Sivalingam A. Surgical management of retinal angiomatous proliferation. *Archives Ophthalmol* 2003;121:558-561.
32. Bressler N, Rosenfeld P, Lim J, for the VIM Study Group: A phase II placebo-controlled, double-masked, randomized trial: verteporfin in minimally classic CNV due to AMD (VIM) []. *Invest Ophthalmol Vis Sci* 2003; 44: E- 1100.
33. Bressler NM, Bressler SB, Childs AL, et al: Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13. *Ophthalmology* 2004 Nov; 111(11): 1993-2006.
34. Bressler NM, Bressler SB, Congdon NG, et al. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. *Arch Ophthalmol*. 2003;121:1621-1624.
35. Bressler NM, for the TAP Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. *Arch Ophthalmol* 2001 Feb; 119(2): 198-207.
36. Bressler NM: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization. *Am J Ophthalmol* 2002 Jan; 133(1): 168-9.
37. Bressler SB, Bressler NM, Fine SL, Hillis A, Murphy RP, Olk RJ, et al. Natural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration. *Am J Ophthalmol*. Feb 1982;93(2):157-63. .
38. Brody BL, Gamst AC, Williams RA, et al: Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. *Ophthalmology* 2001 Oct; 108(10): 1893-900; discussion 1900-1.
39. Brooks HL Jr, Caballero S Jr, Newell CK, et al. Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. *Arch Ophthalmol*. 2004;122:1801-1807.
40. Brown DM, Ianchelev T, Yue H, Shams N. Phase IIIb, multicenter, randomized, double-masked, sham injection-controlled study of the efficacy and safety of ranibizumab in patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD): first-year results of the PIER study. Program and s of the Canadian Ophthalmological Society 2006 Annual Meeting and Exposition; June 21-24, 2006; Toronto, Ontario, Canada.
41. Bucher RS, Hall E, Reed DM, et al. Effect of intravitreal triamcinolone acetonide on susceptibility to experimental bacterial endophthalmitis and subsequent response to treatment. *Arch Ophthalmol*. 2005;123:649-653.
42. CDC Fact Sheet. Number of Americans with diabetes continues to increase. October 26, 2005. <http://www.cdc.gov/od/oc/media/pressrel/fs051026.htm>
43. Cekic O, Chang S, Tseng JJ, et al. Cataract progression after intravitreal triamcinolone injection. *Am J Ophthalmol*. 2005;139:993-998.

BIBLIOGRAPHY: Clinical Retina

44. Challa JK, Gillies MC, Penfold PL, et al: Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. *Aust N Z J Ophthalmol* 1998 Nov; 26(4): 277-81.
45. Chang CW, Chu G, Hinz BJ, Greve MD. Current use of dietary supplementation in patients with age-related macular degeneration. *Can J Ophthalmol*. 2003;38:27-32.
46. Char DH, Irvine AI, Posner MD, et al: Randomized trial of radiation for age-related macular degeneration. *Am J Ophthalmol* 1999 May; 127(5): 574-8.
47. Chau FY, Koreishi A, Bearely S, Izatt JA, Toth CA. Spectral domain OCT imaging of retinal layers at the margins of geographic atrophy. Program and s of the American Academy of Ophthalmology 2007 Annual Meeting; November 10-13, 2007; New Orleans, Louisiana. Poster 463.
48. Chew EY; the Age-Related Eye Disease Study II Research Group. Retina 2005: Changing concepts and controversies: AREDS II. Program and s of the American Academy of Ophthalmology 109th Annual Meeting; October 15-18, 2005; Chicago, Illinois.
49. Chopdar A, Chakravarthy U, Verma D. Age related macular degeneration. *BMJ*. 2003;326:485-488.
50. Christen WG, Glynn RJ, Manson JE, et al: A prospective study of cigarette smoking and risk of age-related macular degeneration in men. *JAMA* 1996 Oct 9; 276(14): 1147-51.
51. Ciulla TA, Criswell MH, Danis RP, et al: Choroidal neovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetate microimplants. *Br J Ophthalmol* 2003 Aug; 87(8): 1032-7.
52. Ciulla TA, Criswell MH, Danis RP, et al: Squalamine lactate reduces choroidal neovascularization in a laser-injury model in the rat. *Retina* 2003 Dec; 23(6): 808-14.
53. Ciulla TA, Danis RP, Klein SB, et al: Proton therapy for exudative age-related macular degeneration: a randomized, sham-controlled clinical trial. *Am J Ophthalmol* 2002 Dec; 134(6): 905-6.
54. Ciulla TA, Harris A, Kagemann L, et al: Transpupillary thermotherapy for subfoveal occult choroidal neovascularization: effect on ocular perfusion. *Invest Ophthalmol Vis Sci* 2001 Dec; 42(13): 3337-40.
55. Clark AF, Mellon J, Li XY, et al: Inhibition of intraocular tumor growth by topical application of the angiostatic steroid anecortave acetate. *Invest Ophthalmol Vis Sci* 1999 Aug; 40(9): 2158-62.
56. Clark AF. AL-3789: a novel ophthalmic angiostatic steroid. *Expert Opin Investig Drugs*. 1997;6:1867-1877.
57. Clemons TE, Kurinij N, Sperduto RD, AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the Age-Related Eye Disease Study. AREDS report no. 13. *Arch Ophthalmol*. 2004;122:716-726.
58. Coleman AL, Stone K, Ewing SK, et al: Higher risk of multiple falls among elderly women who lose visual acuity. *Ophthalmology* 2004 May; 111(5): 857-62.

BIBLIOGRAPHY: Clinical Retina

59. Coleman HR, Barbazetto IA, Costa D, et al. Prevalence of retinal angiomatous proliferation in exudative age related macular degeneration within a retinal practice. Manuscript submitted to Ophthalmology.
60. Cruickshanks KJ, Klein R, Klein BE: Sunlight and age-related macular degeneration. The Beaver Dam Eye Study. Arch Ophthalmol 1993 Apr; 111(4): 514-8.
61. Crum R, Szabo S, Folkman J: A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 1985 Dec 20; 230(4732): 1375-8.
62. Curcio CA, Millican CL, Bailey T, Kruth HS. Accumulation of cholesterol with age in human Bruch's membrane. Invest Ophthalmol Vis Sci. 2001;42:265-274.
63. D'Amico D, Bird A: VEGF inhibition study in ocular neovascularization-1 (VISION-1): safety evaluation from the pivotal Macugen (pegaptanib sodium) clinical trials [E-]. Invest Ophthalmol Vis Sci 2004; 45: 2363.
64. D'Amico DJ, Goldberg MF, Hudson H, et al. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology. 2003;110:2372-2383.
65. Danis RP, Bingaman DP, Yang Y, Ladd B. Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology. 1996;103:2099-2104.
66. Danis RP, Ciulla TA, Pratt LM, Anliker W: Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000; 20(3): 244-50.
67. Das BN, Thompson JR, Patel R, Rosenthal AR: The prevalence of eye disease in Leicester: a comparison of adults of Asian and European descent. J R Soc Med 1994 Apr; 87(4): 219-22.
68. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science. Jul 9 1999;285(5425):245-8. .
69. de Juan E Jr, Loewenstein A, Bressler NM, Alexander J. Translocation of the retina for management of subfoveal choroidal neovascularization II: a preliminary report in humans. Am J Ophthalmol. May 1998;125(5):635-46. .
70. Del Priore LV, Kaplan HJ, Hornbeck R, et al: Retinal pigment epithelial debridement as a model for the pathogenesis and treatment of macular degeneration. Am J Ophthalmol 1996 Nov; 122(5): 629-43.
71. Donati G, Soubrane D, Quaranta M, et al: Radiotherapy for isolated occult subfoveal neovascularisation in age related macular degeneration: a pilot study. Br J Ophthalmol 1999 Jun; 83(6): 646-51.
72. Dong LM, Childs AL, Mangione CM, et al: Health- and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials of submacular surgery: SST report no. 4. Am J Ophthalmol 2004 Jul; 138(1): 91-108.
73. Donoso LA, Kim D, Frost A, Callahan A, Hageman G. The role of inflammation in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2006;51:137-152.

BIBLIOGRAPHY: Clinical Retina

74. Drexler W, Sattmann H, Hermann B, et al: Enhanced visualization of macular pathology with the use of ultrahigh-resolution optical coherence tomography. *Arch Ophthalmol* 2003 May; 121(5): 695-706.
75. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. *Am J Pathol.* 1995;146:1029-1039.
76. Eagle RC: Mechanisms of maculopathy. *Ophthalmology* 1984 Jun; 91(6): 613-25.
77. Edwards AO, Ritter R, Abel KJ, et al. Complement factor H polymorphism and age-related macular degeneration. *Science.* 2005;308:421-424.
78. Eldred GE. Lipofuscin fluorophore inhibits lysosomal protein degradation and may cause early stages of macular degeneration. *Gerontology.* 1995;41(suppl 2):15-28.
79. Emerson MV, Lauer AK, Flaxel CJ, Wilson DJ, Francis PJ, Stout JT, et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. *Retina.* Apr-May 2007;27(4):439-44. .
80. Espinosa-Heidmann DG, Suner IJ, Hernandez EP, et al. Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. *Invest Ophthalmol Vis Sci.* 2003;44:3586-3592.
81. Eyetech Study Group: Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. *Ophthalmology* 2003 May; 110(5): 979-86.
82. Eyetech Study Group: Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. *Retina* 2002 Apr; 22(2): 143-52.
83. Fernandes LH, Freund KB, Yannuzzi LA, Spaide RF, Huang SJ, Slakter JS, Sorenson JA. The nature of focal areas of hyperfluorescence of "hot pots" imaged with indocyanine green angiography. *Retina* 2002;22(5):557-68.
84. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. *Nat Med.* 2003;9:669-676.
85. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. *Biochem Biophys Res Commun.* 1989;161:851-858.
86. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. *Arch Ophthalmol.* Nov 1984;102(11):1640-2. .
87. Finger PT, Berson A, Ng T, Szechter A: Ophthalmic plaque radiotherapy for age-related macular degeneration associated with subretinal neovascularization. *Am J Ophthalmol* 1999 Feb; 127(2): 170-7.
88. Finger PT, Berson A, Sherr D, et al: Radiation therapy for subretinal neovascularization. *Ophthalmology* 1996 Jun; 103(6): 878-89.
89. Folk JC, Reddy CV. White dot chorioretinal inflammatory syndromes. In: *Medical and Surgical Retina Advances, Controversies, and Management.* 1994;385-399.
90. Folkman J, Ingber DE: Angiostatic steroids. Method of discovery and mechanism of action. *Ann Surg* 1987 Sep; 206(3): 374-83.
91. Folkman J. Tumor angiogenesis: therapeutic implications. *N Engl J Med.* 1971;285:1182-1186.

BIBLIOGRAPHY: Clinical Retina

92. Fraser-Bell S, Wu J, Klein R, Azen SP, Varma R. Smoking, alcohol intake, estrogen use, and age-related macular degeneration in Latinos: the Los Angeles Latino Eye Study. *Am J Ophthalmol*. 2006;141:79-87.
93. Freund KB, Laud K, Eandi CM, Spaide RF. Silicone oil droplets following intravitreal injection. *Retina*. 2006;26:701-703.
94. Freund KB, Yannuzzi LA, Sorenson JA: Age-related macular degeneration and choroidal neovascularization. *Am J Ophthalmol* 1993 Jun 15; 115(6): 786-91.
95. Freund KB, Yannuzzi LA, Spaide RF: Feeder vessel photocoagulation for subfoveal CNV. *Ophthalmology* 1998 Dec; 105(12): 2164-5.
96. Friedman DS, Katz J, Bressler NM, Rahmani B, Tielsch JM. Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey. *Ophthalmology*. 1999;106:1049-1055.
97. Friedman DS, O'Colmain BJ, Munoz B, et al, for the Eye Diseases Prevalence Research Group: Prevalence of age-related macular degeneration in the United States. *Arch Ophthalmol* 2004 Apr; 122(4): 564-72.
98. Friedman E, Krupsky S, Lane AM, et al: Ocular blood flow velocity in age-related macular degeneration. *Ophthalmology* 1995 Apr; 102(4): 640-6.
99. Friedman E: A hemodynamic model of the pathogenesis of age-related macular degeneration. *Am J Ophthalmol* 1997 Nov; 124(5): 677-82.
100. Friedman SM, Margo CE. Choroidal neovascular membranes: reproducibility of angiographic interpretation. *Am J Ophthalmol*. 2000;130:839-841.
101. Fuller B, Gitter KA. Traumatic choroidal rupture with late serous detachment of macula. Report of successful argon laser treatment. *Arch Ophthalmol*. Apr 1973;89(4):354-5. .
102. Gaillard ER, Atherton SJ, Eldred G, Dillon J. Photophysical studies on human retinal lipofuscin. *Photochem Photobiol*. 1995;61:448-453.
103. Genaidy M, Kazi AA, Peyman GA, et al: Effect of squalamine on iris neovascularization in monkeys. *Retina* 2002 Dec; 22(6): 772-8.
104. Gillies MC, Simpson JM, Luo W, et al: A randomized clinical trial of a single dose of intravitreal triamcinolone acetate for neovascular age-related macular degeneration: one-year results. *Arch Ophthalmol* 2003 May; 121(5): 667-73.
105. Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. *Retina*. Apr-May 2007;27(4):432-8. .
106. Goldberg J, Flowerdew G, Smith E, et al. Factors associated with age-related macular degeneration: an analysis of data from the first National Health and Nutrition Examination Survey. *Am J Epidemiol*. 1988;128:700-710.
107. Gonzalez J: Visudyne benefits patients with minimally classic lesion at 1 year. *Ocular Surg News* 2003; 21(16): 40, 48.
108. Gouras P, Algvere P: Retinal cell transplantation in the macula: new techniques. *Vision Res* 1996 Dec; 36(24): 4121-5.
109. Gragoudas E: VEGF Inhibition Study in Ocular Neovascularization-1 (VISION-1): efficacy results from phase II/III Macugen (pegaptanib sodium) clinical trials []. *Invest Ophthalmol Vis Sci* 2004; 45(E- 2364).

BIBLIOGRAPHY: Clinical Retina

110. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. Pegatanib for neovascular age-related macular degeneration. *New Eng J Med*. 2004;351:2805-2816.
111. Graham RO, Peyman GA. Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis. *Arch Ophthalmol*. 1974;92:149-154.
112. Green WR, Key SN 3rd. Senile macular degeneration: a histopathologic study. 1977. *Retina*. 2005;25(5 suppl):180-250.
113. Grisanti S, Tatar O, Canbek S, et al: Immunohistopathologic evaluation of choroidal neovascular membranes following verteporfin-photodynamic therapy. *Am J Ophthalmol* 2004 May; 137(5): 914-23.
114. Gross JG, King LP, de Juan E Jr, Powers T. Subfoveal neovascular membrane removal in patients with traumatic choroidal rupture. *Ophthalmology*. Apr 1996;103(4):579-85. .
115. Grossniklaus HE, Green WR. Histopathologic and ultrastructural findings of surgically excised choroidal neovascularization. Submacular Surgery Trials Research Group. *Arch Ophthalmol*. Jun 1998;116(6):745-9. .
116. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. *Proc Natl Acad Sci USA*. 2005;102:7227-7232.
117. Hageman GS, Luthert PJ, Victor Chong NH, et al. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. *Prog Retin Eye Res*. 2001;20:705-732.
118. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. *Science*. 2005;308:419-421.
119. Hartnett ME, Weiter JJ, Gardts A, Jalkh AE. Classification of retinal pigment epithelial detachments associated with drusen. *Graefes Arch Clin Exp Ophthalmol* 1992;230:11-19.
120. Hartnett ME, Weiter JJ, Staurengi G, Elsner AE. Deep retinal vascular anomalous complexes in advanced age-related macular degeneration. *Ophthalmology* 1996;103:2042-2053.
121. Hawkins BS, Bressler NM, Miskala PH, et al: Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report no. 11. *Ophthalmology* 2004 Nov; 111(11): 1967-80.
122. Hee MR, Bauman CR, Puliafito CA, et al: Optical coherence tomography of age-related macular degeneration and choroidal neovascularization. *Ophthalmology* 1996 Aug; 103(8): 1260-70.
123. Heeschen C, Jang JJ, Weis M, et al. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. *Nat Med*. 2001;7:833-839.
124. Heier J, Sy J, McCluskey E: RhuFab V2 Study Group. RhuFab V2 in wet AMD - 6 month continued improvement following multiple intravitreal injections. *Invest Ophthalmol Vis Sci* 2003; 44: E- 972.
125. Heier J: Anti-VEGF: Genentech-Ranibizumab. In: Program of the Annual Meeting of the American Academy of Ophthalmology. Retina Subspecialty Day: October 22, 2004. Supplement. San Francisco, CA: American Academy of Ophthalmology; 2004: 38.

BIBLIOGRAPHY: Clinical Retina

126. Heier JS, Shapiro H, Singh AA Sr; MARINA Study Group. Randomized, controlled phase III study of ranibizumab (Lucentis) for minimally classic or occult neovascular age-related macular degeneration: two-year efficacy results of the MARINA study. Program and s of the Association for Research in Vision and Ophthalmology; April 30-May 4, 2006; Fort Lauderdale, Florida. 2959.
127. Heimann K: A breakthrough in surgery for age-related macular degeneration? Graefes Arch Clin Exp Ophthalmol 1994 Dec; 232(12): 706.
128. Heimann, H et al, Atlas of Fundus Angiography, Stuggart: Thieme, 2006.
129. Heriot W: Corticosteroids for AMD. In: Program of the Annual Meeting of the American Academy of Ophthalmology, Retina Subspecialty Day: October 22, 2004. Supplement. San Francisco, CA: American Academy of Ophthalmology; 2004: 24-5.
130. Higgins RD, Sanders RJ, Yan Y, et al: Squalamine improves retinal neovascularization. Invest Ophthalmol Vis Sci 2000 May; 41(6): 1507-12.
131. Ho AC, Yannuzzi LA, Pisicano K, DeRosa J. The natural history of idiopathic subfoveal choroidal neovascularization. Ophthalmology. May 1995;102(5):782-9. .
132. Holash J, Davis S, Papadopoulos N, et al: VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002 Aug 20; 99(17): 11393-8.
133. Holekamp NM, Bouck N, Volpert O: Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. Am J Ophthalmol 2002 Aug; 134(2): 220-7.
134. Holekamp NM, Thomas MA, Pearson A: The safety profile of long-term, high-dose intraocular corticosteroid delivery. Am J Ophthalmol 2005 Mar; 139(3): 421-8.
135. Hope-Ross MW, Gibson JM, Chell PB, et al: Dye enhanced laser photocoagulation in the treatment of a peripapillary subretinal neovascular membrane. Acta Ophthalmol (Copenh) 1994 Feb; 72(1): 134-7.
136. Horiuchi T, Weller PF. Expression of vascular endothelial growth factor by human eosinophils: upregulation by granulocyte macrophage colony-stimulating factor and interleukin-5. Am J Respir Cell Mol Biol. 1997;17:70-77.
137. Hudson HL, Frambach DA, Lopez PF: Relation of the functional and structural fundus changes after submacular surgery for neovascular age-related macular degeneration. Br J Ophthalmol 1995 May; 79(5): 417-23.
138. Hunt DW, Jiang H, Granville DJ, et al: Consequences of the photodynamic treatment of resting and activated peripheral T lymphocytes. Immunopharmacology 1999 Jan; 41(1): 31-44.
139. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
140. Husain D, Kim I, Gauthier D, et al: Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol 2005 Apr; 123(4): 509-16.
141. Hyman LG, Lilienfeld AM, Ferris FL 3rd, Fine SL. Senile macular degeneration: a case-control study. Am J Epidemiol. 1983;118:213-227.
142. Ignoffo RJ. Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor. Am J Health Syst Pharm. 2004;61(21 suppl 5):S21-S26.

BIBLIOGRAPHY: Clinical Retina

143. Ishibashi T, Miki K, Sorgente N, et al: Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. *Arch Ophthalmol* 1985 May; 103(5): 708-11.
144. Jonas J, Degenring R, Kreissig I, et al: Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide [advanced online publication]. Available at: <http://www.nature.com/cgi-taf/DynaPage.taf?file=/eye/journal/vaop/ncurrent/abs/670>. *Eye*; 2004.
145. Jonas JB, Akkoyun I, Budde WM, Kreissig I, Degenring RF. Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. *Arch Ophthalmol*. 2004;122:218-222.
146. Jonas JB, Kreissig I, Degenring R: Intraocular pressure after intravitreal injection of triamcinolone acetonide. *Br J Ophthalmol* 2003 Jan; 87(1): 24-7.
147. Jonas JB, Kreissig I, Hugger P, et al: Intravitreal triamcinolone acetonide for exudative age related macular degeneration. *Br J Ophthalmol* 2003 Apr; 87(4): 462-8.
148. Jonas JB, Kreissig I, Hugger P, Sauder G, Panda-Jonas S, Degenring R. Intravitreal triamcinolone acetonide for exudative age related macular degeneration. *Br J Ophthalmol*. 2003;87:462-468.
149. Kahn HA, Leibowitz HM, Ganley JP: The Framingham Eye Study, I: outline and major prevalence findings. *Am J Epidemiol* 1977 Jul; 106(1): 17-32.
150. Kaiser P. Anchor data. Program of Macula 2006; January 13-14, 2006; New York, NY.
151. Kaluzny JJ, Wojtkowski M, Sikorski B, et al. Different forms of CNV on spectral OCT thickness maps. Program and s of the American Academy of Ophthalmology 2007 Annual Meeting; November 10-13, 2007; New Orleans, Louisiana. Poster 230.
152. Katz ML, Parker KR, Handelman GJ, et al: Effects of antioxidant nutrient deficiency on the retina and retinal pigment epithelium of albino rats: a light and electron microscopic study. *Exp Eye Res* 1982 Mar; 34(3): 339-69.
153. Kerr DJ. Targeting angiogenesis in cancer: clinical development of bevacizumab. *Nat Clin Pract Oncol*. 2004;1:39-43.
154. Khan BU, Lam W-C. Diabetic Macular Edema. Last updated April 14, 2006. <http://www.emedicine.com/oph/topic399.htm>
155. Kini MM, Leibowitz HM, Colton T, et al: Prevalence of senile cataract, diabetic retinopathy, senile macular degeneration, and open-angle glaucoma in the Framingham eye study. *Am J Ophthalmol* 1978 Jan; 85(1): 28-34.
156. Klaver CC, Wolfs RC, Vingerling JR, et al: Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. *Arch Ophthalmol* 1998 May; 116(5): 653-8.
157. Klein BE, Klein R, Lee KE, Jensen SC: Measures of obesity and age-related eye diseases. *Ophthalmic Epidemiol* 2001 Sep; 8(4): 251-62.
158. Klein R, Klein BE, Jensen SC, et al. Age-related maculopathy in a multiracial United States population: the National Health and Nutrition Examination Survey III. *Ophthalmology*. 1999;106:1056-1065.

BIBLIOGRAPHY: Clinical Retina

159. Klein R, Klein BE, Jensen SC, Meuer SM: The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. *Ophthalmology* 1997 Jan; 104(1): 7-21.
160. Klein R, Klein BE, Linton KL: Prevalence of age-related maculopathy. The Beaver Dam Eye Study. *Ophthalmology* 1992 Jun; 99(6): 933-43.
161. Klein R, Rowland ML, Harris MI: Racial/ethnic differences in age-related maculopathy. Third National Health and Nutrition Examination Survey. *Ophthalmology* 1995 Mar; 102(3): 371-81.
162. Klein RJ, Zeiss C, Chew EY, et al: Complement factor H polymorphism in age-related macular degeneration. *Science* 2005 Apr 15; 308(5720): 385-9.
163. Krott R, Staar S, Muller RP, et al: External beam radiation in patients suffering from exudative age-related macular degeneration. A matched-pairs study and 1-year clinical follow-up. *Graefes Arch Clin Exp Ophthalmol* 1998 Dec; 236(12): 916-21.
164. Kuhn D, Meunier I, Soubrane G, Coscas G. Imaging of chorioretinal anastomoses in vascularized retinal pigment epithelium detachments. *Arch Ophthalmol* 1995;113:1392–1398.
165. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. *Invest Ophthalmol Vis Sci.* 1996;37:1929-1934.
166. Kvanta A: Expression and regulation of vascular endothelial growth factor in choroidal fibroblasts. *Curr Eye Res* 1995 Nov; 14(11): 1015-20.
167. Lambert HM, Capone A Jr, Aaberg TM, Sternberg P Jr, Mandell BA, Lopez PF. Surgical excision of subfoveal neovascular membranes in age-related macular degeneration. *Am J Ophthalmol.* Mar 15 1992;113(3):257-62. .
168. Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. *Arch Ophthalmol.* 1994;112:500-509.
169. Laud K, Spaide RF, Freund KB, Slakter J, Klancnik JM Jr. Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. *Retina.* Oct 2006;26(8):960-3. .
170. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. *Ophthalmology.* Jun 2007;114(6):1179-85. .
171. Leibowitz HM, Krueger DE, Maunder LR, et al: The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. *Surv Ophthalmol* 1980 May-Jun; 24(Suppl): 335-610.
172. Lewis H, Kaiser PK, Lewis S, et al: Macular translocation for subfoveal choroidal neovascularization in age-related macular degeneration: a prospective study. *Am J Ophthalmol* 1999 Aug; 128(2): 135-46.
173. Light Sciences Corporation: Light Sciences to present at Seattle's Invest Northwest Conference [Light Sciences Corporation Web site]. March 17, 2004. Available at: <http://www.lightsciences.com/news/investnw.html>. Accessed October 15, 2004. .

BIBLIOGRAPHY: Clinical Retina

174. Little CW, Castillo B, DiLoreto DA, et al: Transplantation of human fetal retinal pigment epithelium rescues photoreceptor cells from degeneration in the Royal College of Surgeons rat retina. *Invest Ophthalmol Vis Sci* 1996 Jan; 37(1): 204-11.
175. Lopez PF, Sippy BD, Lambert HM, et al: Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. *Invest Ophthalmol Vis Sci* 1996 Apr; 37(5): 855-68.
176. Lowe J, Araujo J, Palma M, et al. RhuFab V2 inhibits VEGF-isoforms-stimulated HUVEC proliferation. *Invest Ophthalmol Vis Sci*. 2003;44: 1828.
177. LuEsther T. Mertz Retinal Research Center: Study compares early vs standard Visudyne therapy for AMD. Available at: http://www.retinal-research.org/study_descriptions.htmlvisudyne. Accessed October 11, 2003. .
178. Machemer R, Steinhorst UH. Retinal separation, retinotomy, and macular relocation: II. A surgical approach for age-related macular degeneration?. *Graefes Arch Clin Exp Ophthalmol*. Nov 1993;231(11):635-41. .
179. Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial. *Arch Ophthalmol*. 1990;108:816-824.
180. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of randomized clinical trial. *Arch Ophthalmol*. 1991;109:1220-1231.
181. Macular Photocoagulation Study Group. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. The influence of initial lesion size and initial visual acuity. *Arch Ophthalmol*. 1994;112:480-488.
182. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. *Arch Ophthalmol*. Aug 1991;109(8):1109-14.
183. Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. *Arch Ophthalmol*. Apr 1994;112(4):500-9.
184. Mandelcorn MS, Menezes AV: Surgical removal of subretinal hemorrhage and choroidal neovascular membranes in acute hemorrhagic age-related macular degeneration. *Can J Ophthalmol* 1993 Feb; 28(1): 19-23.
185. Marcus D, Peskin E, Alexander J, et al: The age-related macular degeneration radiotherapy trial (AMDRT): 1-year results [E-]. *Invest Ophthalmol Vis Sci* 2003; 44: 3158.
186. Marcus DM, Sheils W, Johnson MH, et al: External beam irradiation of subfoveal choroidal neovascularization complicating age-related macular degeneration: one-year results of a prospective, double-masked, randomized clinical trial. *Arch Ophthalmol* 2001 Feb; 119(2): 171-80.
187. Mauget-Faysse M, Chiquet C, Milea D, et al: Long term results of radiotherapy for subfoveal choroidal neovascularisation in age related macular degeneration. *Br J Ophthalmol* 1999 Aug; 83(8): 923-8.

BIBLIOGRAPHY: Clinical Retina

188. McCuen BW 2nd, Bessler M, Tano Y, Chandler D, Machemer R. The lack of toxicity of intravitreally administered triamcinolone acetonide. *Am J Ophthalmol*. 1981;91:785-788.
189. McNatt LG, Weimer L, Yanni J, Clark AF: Angiostatic activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularization. *J Ocul Pharmacol Ther* 1999 Oct; 15(5): 413-23.
190. Michaelson IC. The mode of development of the vascular system of the retina with some observations on its significance for certain retinal disorders. *Trans Ophthalmol Soc UK*. 1948;68:137-180.
191. Michels S, Rosenfeld PJ, Puliafito CA, et al: Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. *Ophthalmology* 2005 Jun; 112(6): 1035-47.
192. Miller J, Chung CY, Kim RY, MARINA Study Group. Randomized, controlled phase III study of ranibizumab (Lucentis) for minimally classic or occult neovascular age-related macular degeneration. Program and s of the American Society of Retina Specialists 23rd Annual Meeting; July 16-20, 2005; Montreal, Canada.
193. Miller JW, Shapiro H, Acharya N, for the MARINA Study Group. Randomized, controlled phase III study of ranibizumab (Lucentis) for minimally classic or occult neovascular age-related macular degeneration: two-year safety results of the MARINA study. Program and s of the Association for Research in Vision and Ophthalmology; April 30-May 4, 2006; Fort Lauderdale, Florida. 3539.
194. Miyazaki M, Nakamura H, Kubo M, et al: Risk factors for age related maculopathy in a Japanese population: the Hisayama study. *Br J Ophthalmol* 2003 Apr; 87(4): 469-72.
195. Moisseiev J, Alhalel A, Masuri R, Treister G: The impact of the macular photocoagulation study results on the treatment of exudative age-related macular degeneration. *Arch Ophthalmol* 1995 Feb; 113(2): 185-9.
196. Mori K, Duh E, Gehlbach P, et al: Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. *J Cell Physiol* 2001 Aug; 188(2): 253-63.
197. Moriarty AP: Indocyanine green enhanced diode laser photocoagulation of subretinal neovascular membranes. *Br J Ophthalmol* 1994 Mar; 78(3): 238-9.
198. Moshfeghi DM, Kaiser PK, Scott IU, et al: Acute endophthalmitis following intravitreal triamcinolone acetonide injection. *Am J Ophthalmol* 2003 Nov; 136(5): 791-6.
199. Moshfeghi DM, Peyman GA, Moshfeghi AA, et al: Ocular vascular thrombosis following tin ethyl etiopurpurin (SnET2) photodynamic therapy: time dependencies. *Ophthalmic Surg Lasers* 1998 Aug; 29(8): 663-8.
200. MPS Group: Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. *Arch Ophthalmol* 1991 Aug; 109(8): 1109-14.
201. MPS Group: Macular Photocoagulation Study Group. Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. *Arch Ophthalmol* 1993 Sep; 111(9): 1189-99.

BIBLIOGRAPHY: Clinical Retina

202. MPS Group: Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. *Arch Ophthalmol* 1993 Sep; 111(9): 1200-9.
203. MPS Group: Macular Photocoagulation Study Group. Recurrent choroidal neovascularization after argon laser photocoagulation for neovascular maculopathy. *Arch Ophthalmol* 1986 Apr; 104(4): 503-12.
204. MPS Group: Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. *Arch Ophthalmol* 1991 Sep; 109(9): 1242-57.
205. Mullins RF, Russell SR, Anderson DH, Hageman GS. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. *FASEB J.* 2000;14:835-846.
206. Musch DC, Gillespie BW. The state of being noninferior. *Ophthalmology.* 2006;113:1-2.
207. Nader N: Clinical trials show promise of intravitreal steroids, other therapies for retinal diseases. *Ocular Surg News* 2004; 22(3): 28-30.
208. Nambu H, Nambu R, Melia M, Campochiaro PA: Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization. *Invest Ophthalmol Vis Sci* 2003 Aug; 44(8): 3650-5.
209. National Diabetes Fact Sheet. United States, 2005.
http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2005.pdf
210. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. *Eur J Pharmacol.* 1998;341:309-315.
211. Nawrocki J, Michalewska Z, Nawrocka Z, Michalewski J. New implications of spectral OCT for retinology. Program and s of the American Academy of Ophthalmology 2007 Annual Meeting; November 10-13, 2007; New Orleans, Louisiana. Video 40.
212. Nishiwaki H, Zeimer R, Goldberg MF, et al: Laser targeted photo-occlusion of rat choroidal neovascularization without collateral damage. *Photochem Photobiol* 2002 Feb; 75(2): 149-58.
213. Obana A, Gohto Y, Kanai M, et al: Selective photodynamic effects of the new photosensitizer ATX-S10(Na) on choroidal neovascularization in monkeys. *Arch Ophthalmol* 2000 May; 118(5): 650-8.
214. Ohkuma H, Ryan SJ: Experimental subretinal neovascularization in the monkey. Permeability of new vessels. *Arch Ophthalmol* 1983 Jul; 101(7): 1102-10.
215. Okamoto N, Tobe T, Hackett SF, et al: Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. *Am J Pathol* 1997 Jul; 151(1): 281-91.
216. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. *N Engl J Med.* 1996;334:1150-1155.

BIBLIOGRAPHY: Clinical Retina

217. Ormerod LD, Puklin JE, Frank RN: Long-term outcomes after the surgical removal of advanced subfoveal neovascular membranes in age-related macular degeneration. *Ophthalmology* 1994 Jul; 101(7): 1201-210.
218. Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. *Aust N Z J Ophthalmol.* 1995;23:293-298.
219. Penn JS, Rajaratnam VS, Collier RJ, Clark AF: The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. *Invest Ophthalmol Vis Sci* 2001 Jan; 42(1): 283-90.
220. Peyman GA, Moshfeghi DM, Moshfeghi A, et al: Photodynamic therapy for choriocapillaris using tin ethyl etiopurpurin (SnET2). *Ophthalmic Surg Lasers* 1997 May; 28(5): 409-17.
221. Pharmacological Therapy for Macular Degeneration Study Group. Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. Pharmacological Therapy for Macular Degeneration Study Group. *Arch Ophthalmol.* Jul 1997;115(7):865-72. .
222. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. *Arch Ophthalmol.* 1999;117:1329-1345.
223. Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. *Arch Ophthalmol.* Oct 1999;117(10):1329-45. .
224. Piermarocchi S, Lo Giudice G, Sartore M, et al: Photodynamic therapy increases the eligibility for feeder vessel treatment of choroidal neovascularization caused by age-related macular degeneration. *Am J Ophthalmol* 2002 Apr; 133(4): 572-5.
225. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. *Cancer Res.* 1997;57:4593-4599.
226. RAD Study Group: A prospective, randomized, double-masked trial on radiation therapy for neovascular age-related macular degeneration (RAD Study). *Radiation Therapy for Age-related Macular Degeneration.* *Ophthalmology* 1999 Dec; 106(12): 2239-47.
227. Ranson NT, Danis RP, Ciulla TA, Pratt L: Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. *Br J Ophthalmol* 2002 May; 86(5): 527-9.
228. Rasmussen H, Chu KW, Campochiaro P, et al: Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). *Hum Gene Ther* 2001 Nov 1; 12(16): 2029-32.
229. Reddy GK: The addition of bevacizumab to FOLFOX4 prolongs survival in relapsed colorectal cancer: interim data from the ECOG 3200 trial. *Clin Colorectal Cancer* 2005 Jan; 4(5): 300-1.

BIBLIOGRAPHY: Clinical Retina

230. Reddy VM, Zamora RL, Kaplan HJ: Distribution of growth factors in subfoveal neovascular membranes in age-related macular degeneration and presumed ocular histoplasmosis syndrome. *Am J Ophthalmol* 1995 Sep; 120(3): 291-30.
231. Regillo C, Jerdan J: Anecortave acetate: prevention of AMD. In: Program of the Annual Meeting of the American Academy of Ophthalmology. Retina Subspecialty Day: October 22, 2004. Supplement. San Francisco, CA: American Academy of Ophthalmology; 2004: 10-1.
232. Regillo CD: Update on photodynamic therapy. *Curr Opin Ophthalmol* 2000 Jun; 11(3): 166-70.
233. Reich SJ, Fosnot J, Kuroki A, et al: Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. *Mol Vis* 2003 May 30; 9: 210-6.
234. Reichel E, Berrocal AM, Ip M, et al: Transpupillary thermotherapy of occult subfoveal choroidal neovascularization in patients with age-related macular degeneration. *Ophthalmology* 1999 Oct; 106(10): 1908-14.
235. Reichel E, Puliafito CA, Duker JS, Guyer DR: Indocyanine green dye-enhanced diode laser photocoagulation of poorly defined subfoveal choroidal neovascularization. *Ophthalmic Surg* 1994 Mar; 25(3): 195-201.
236. Reichel E. Photodynamic therapy and corticosteroids for AMD: transpupillary thermotherapy. Retinal Subspecialty Day. Program and s of the American Academy of Ophthalmology and European Society of Ophthalmology 2004 Joint Meeting; October 23-26, 2004; New Orleans, Louisiana.
237. Reinboth JJ, Gautschi K, Munz K, Eldred GE, Reme CE. Lipofuscin in the retina: quantitative assay for an unprecedented autofluorescent compound (pyridinium bis-retinoid, A2-E) of ocular age pigment. *Exp Eye Res.* 1997;65:639-643.
238. Renno RZ, Terada Y, Haddadin MJ, et al: Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2. *Arch Ophthalmol* 2004 Jul; 122(7): 1002-11.
239. Riddle J: PDT: Therapies on the cutting edge. *Jobson's Rev Ophthalmol* 2003; X(8): 40-6.
240. Risk factors for neovascular age-related macular degeneration. The Eye Disease Case-Control Study Group. *Arch Ophthalmol.* 1992;110:1701-1708.
241. Roach L: Macugen ups the anti-AMD ante. *Eyenet* 2004 Apr; 29-30.
242. Roesen B, Scheider A, Kiraly A, et al: [Choroid neovascularization in senile macular degeneration. 1 year follow-up after radiotherapy]. *Ophthalmologe* 1998 Jul; 95(7): 461-5.
243. Rogers AH, Martidis A, Greenberg PB, et al: Optical coherence tomography findings following photodynamic therapy of choroidal neovascularization. *Am J Ophthalmol* 2002 Oct; 134(4): 566-76.
244. Rogers AH, Martidis A, Greenberg PB, Puliafito CA. Optical coherence tomography findings following photodynamic therapy of choroidal neovascularization. *Am J Ophthalmol.* Oct 2002;134(4):566-76. .
245. Rosenfeld P: VIM Study Group. Verteporfin in minimally classic CNV due to AMD (VIM) - two-year results from a phase II controlled clinical trial [E-]. *Invest Ophthalmol Vis Sci* 2004; 45: 2273.

BIBLIOGRAPHY: Clinical Retina

246. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. *N Engl J Med*. Oct 5 2006;355(14):1419-31. .
247. Rosenfeld PJ, Fung AE, Lalwani GA, Michels S, Venkatraman AS, Puliafito CA. Visual acuity outcomes following a variable-dosing regimen for ranibizumab (Lucentis) in neovascular AMD: the PrONTO Study. Program and s of the Association for Research in Vision and Ophthalmology; April 30-May 4, 2006; Fort Lauderdale, Florida. 2958.
248. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. *Ophthalmic Surg Lasers Imaging*. Jul-Aug 2005;36(4):331-5. .
249. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial results. *Ophthalmol Clin North Am*. Sep 2006;19(3):361-72. .
250. Rosenfeld PJ. Intravitreal avastin: the low cost alternative to lucentis?. *Am J Ophthalmol*. Jul 2006;142(1):141-3. .
251. Roth DB, Downie AA, Charles ST. Visual results after submacular surgery for neovascularization in age-related macular degeneration. *Ophthalmic Surg Lasers*. Nov 1997;28(11):920-5. .
252. Ruberti JW, Curcio CA, Millican CL, et al. Quick-freeze/deep-etch visualization of age-related lipid accumulation in Bruch's membrane. *Invest Ophthalmol Vis Sci*. 2003;44:1753-1759.
253. Sahni J, Stanga P, Wong D, Harding S: Optical coherence tomography in photodynamic therapy for subfoveal choroidal neovascularisation secondary to age related macular degeneration: a cross sectional study. *Br J Ophthalmol* 2005 Mar; 89(3): 316-20.
254. Saishin Y, Saishin Y, Takahashi K, et al: VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. *J Cell Physiol* 2003 May; 195(2): 241-8.
255. Sasai K, Murata R, Mandai M, et al: Radiation therapy for ocular choroidal neovascularization (phase I/II study): preliminary report. *Int J Radiat Oncol Biol Phys* 1997 Aug 1; 39(1): 173-8.
256. Schalch W: Carotenoids in the retina--a review of their possible role in preventing or limiting damage caused by light and oxygen. *EXS* 1992; 62: 280-98.
257. Schmidt-Erfurth U, Hasan T, Gragoudas E, Michaud N, Flotte TJ, Birngurber R. Vascular targeting in photodynamic occlusion of subretinal vessels. *Ophthalmology*. 1994;101:1953-1961.
258. Schmidt-Erfurth U, Michels S, Michels R, Aue A. Anecortave acetate for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. *Eur J Ophthalmol*. 2005;15:482-485.
259. Schmidt-Erfurth U, Miller J, Sickenberg M, Bunse A, Laqua H, Gragoudas E, et al. Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples. *Graefes Arch Clin Exp Ophthalmol*. May 1998;236(5):365-74. .
260. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF),

BIBLIOGRAPHY: Clinical Retina

- VEGF receptor 3, and pigment epithelium-derived factor. *Invest Ophthalmol Vis Sci.* 2003;44:4473-4480.
261. Schultz J: Significant clinical benefit of TTT seen in subset of patients in CNV trial. *Ocular Surgery News* 2005; 23(8): 56-7.
 262. Schwartz S: Anti-VEGF: Eyetech - Macugen. In: Program of the Annual Meeting of the American Academy of Ophthalmology, Retina Subspecialty Day: October 22, 2004. Supplement. San Francisco, CA: American Academy of Ophthalmology; 2004: 35-7.
 263. Sears J, Capone A Jr, Aaberg T Sr, Lewis H, Grossniklaus H, Sternberg P Jr, et al. Surgical management of subfoveal neovascularization in children. *Ophthalmology.* May 1999;106(5):920-4. .
 264. Seddon J: *Epidemiology of Age-Related Macular Degeneration.* St Louis, MO: Mosby; 2001; 1039-50.
 265. Seddon JM, Ajani UA, Sperduto RD, et al: Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group. *JAMA* 1994 Nov 9; 272(18): 1413-20.
 266. Seddon JM, Cote J, Davis N, Rosner B: Progression of age-related macular degeneration: association with body mass index, waist circumference, and waist-hip ratio. *Arch Ophthalmol* 2003 Jun; 121(6): 785-92.
 267. Seddon JM, Cote J, Rosner B. Progression of age-related macular degeneration: association with dietary fat, transunsaturated fat, nuts, and fish intake. *Arch Ophthalmol.* 2003;121:1728-1737.
 268. Seddon JM, George S, Rosner B. Cigarette smoking, fish consumption, omega-3 fatty acid intake, and associations with age-related macular degeneration: the US Twin Study of Age-Related Macular Degeneration. *Arch Ophthalmol.* 2006;124:995-1001.
 269. Seddon JM, Rosner B, Sperduto RD, et al. Dietary fat and risk for advanced age-related macular degeneration. *Arch Ophthalmol.* 2001;119:1191-1199.
 270. Seddon JM, Willett WC, Speizer FE, Hankinson SE. A prospective study of cigarette smoking and age-related macular degeneration in women. *JAMA.* 1996;276:1141-1146.
 271. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. *Science.* 1983;219:983-985.
 272. Shah GK, Stein JD, Sharma S, et al. Visual outcomes following the use of intravitreal steroids in the treatment of postoperative endophthalmitis. *Ophthalmology.* 2000;107:486-489.
 273. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). *Retina.* 2006;26:262-269.
 274. Shiraga F, Ojima Y, Matsuo T, et al: Feeder vessel photocoagulation of subfoveal choroidal neovascularization secondary to age-related macular degeneration. *Ophthalmology* 1998 Apr; 105(4): 662-9.
 275. Shiraga F, Ojima Y, Matsuo T, Takasu I, Matsuo N. Feeder vessel photocoagulation of subfoveal choroidal neovascularization secondary to age-related macular degeneration. *Ophthalmology.* Apr 1998;105(4):662-9. .

BIBLIOGRAPHY: Clinical Retina

276. Singerman L, Rosenfeld P, for the VALIO Study Group: Verteporfin with altered (delayed) light in occult (VALIO) - 12-month results of a phase II controlled clinical trial. *Invest Ophthalmol Vis Sci* 2004; 45: E- 2274.
277. Sivagnanavel V, Evans JR, Ockrim Z, Chong V. Radiotherapy for neovascular age-related macular degeneration. *Cochrane Database Syst Rev*. 2004;(4):CD004004. .
278. Slakter J, Rosenfeld P, for the VALIO Study Group: Verteporfin with altered (delayed) light in occult CNV (VALIO) - Results of a phase II controlled clinical trial. *Invest Ophthalmol Vis Sci* 2003; 44: E- 1101.
279. Slakter JS, Bochow TW, D'Amico DJ, et al. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. *Ophthalmology*. 2006;113:3-13.
280. Slakter JS, Yannuzzi LA, Schneider U, et al. Retinal choroidal anastomoses and occult choroidal neovascularization in age-related macular degeneration. *Ophthalmology* 2000;107:742–754.
281. Slakter JS. Anecortave acetate for treating or preventing choroidal neovascularization. *Ophthalmol Clin North Am*. 2006;19:373-380.
282. Smith BT, Belani S, Ho AC. Light energy, cataract surgery, and progression of age-related macular degeneration. *Curr Opin Ophthalmol*. 2005;16:166-169.
283. Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: Pooled findings from three continents. *Ophthalmology*. 2001;108:697-704.
284. Smith W, Mitchell P, Leeder SR. Dietary fat and fish intake and age-related maculopathy. *Arch Ophthalmol*. 2000;118:401-404.
285. Smith W, Mitchell P, Wang JJ. Gender, oestrogen, hormone replacement and age-related macular degeneration: results from the Blue Mountains Eye Study. *Aust N Z J Ophthalmol*. 1997;25(suppl 1):S13-S15.
286. Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. *Am J Ophthalmol*. 2004;138:740-743.
287. Snodderly DM, Auran JD, Delori FC: The macular pigment. II. Spatial distribution in primate retinas. *Invest Ophthalmol Vis Sci* 1984 Jun; 25(6): 674-85.
288. Sommer A, Tielsch JM, Katz J, et al: Racial differences in the cause-specific prevalence of blindness in east Baltimore. *N Engl J Med* 1991 Nov 14; 325(20): 1412-7.
289. Spaide R. New treatments for AMD. *Ophthalmology*. 2006;113:160-161.
290. Spaide R: External beam radiation therapy for choroidal neovascularization. Paper presented at: International Symposium on Radiation Therapy for Macular Degeneration; 1997; New York, NY.
291. Spaide RF, Guyer DR, McCormick B, et al: External beam radiation therapy for choroidal neovascularization. *Ophthalmology* 1998 Jan; 105(1): 24-30.
292. Spaide RF, Guyer DR, McCormick B, Yannuzzi LA, Burke K, Mendelsohn M, et al. External beam radiation therapy for choroidal neovascularization. *Ophthalmology*. Jan 1998;105(1):24-30. .
293. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. *Retina*. 2006;26:383-390.

BIBLIOGRAPHY: Clinical Retina

294. Spaide RF, Laud K, Fine HF, Klanchnik JM, Meyerle CB, Yannuzzi LA, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. *Retina*. Apr 2006;26(4):383-90. .
295. Spaide RF, Maranan L. Neutrophil margination as a possible mechanism for Verteporfin Infusion-Associated Pain. *Am J Ophthalmol*. 2003;135:549-550.
296. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy and intravitreal triamcinolone for nonsubfoveal choroidal neovascularization. *Retina*. 2005;25:685-690.
297. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. *Ophthalmology*. Feb 2005;112(2):301-4. .
298. Spaide RF. Aetiology of late age-related macular disease. In: Holz F, Spaide RF, eds. *Medical Retinal (Essentials in Ophthalmology)*. New York, NY: Springer; 2005:95-116.
299. Spaide RF. Rationale for combination therapies for choroidal neovascularization. *Am J Ophthalmol*. 2006;14:149-156.
300. Sparrow JR, Nakanishi K, Parish CA. The lipofuscin fluorophore A2E mediates blue light-induced damage to retinal pigmented epithelial cells. *Invest Ophthalmol Vis Sci*. 2000;41:1981-1989.
301. Staar S, Krott R, Mueller RP, et al: External beam radiotherapy for subretinal neovascularization in age-related macular degeneration: is this treatment efficient? *Int J Radiat Oncol Biol Phys* 1999 Sep 1; 45(2): 467-73.
302. Staurenghi G, Orzalesi N, La Capria A, Aschero M. Laser treatment of feeder vessels in subfoveal choroidal neovascular membranes: a revisitiation using dynamic indocyanine green angiography. *Ophthalmology*. Dec 1998;105(12):2297-305. .
303. Steen B, Sejersen S, Berglin L, Seregard S, Kvanta A. Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. *Invest Ophthalmol Vis Sci*. Oct 1998;39(11):2194-200. .
304. Stellmach V, Crawford SE, Zhou W: Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. *Proc Natl Acad Sci U S A* 2001 Feb 27; 98(5): 2593-7.
305. Sternberg P Jr, Lewis H. Photodynamic therapy for age-related macular degeneration: a candid appraisal. *Am J Ophthalmol*. Mar 2004;137(3):483-5. .
306. Stone EM, Lotery AJ, Munier FL, et al: A single EFEMP1 mutation associated with both Malattia Leventinese and Doyme honeycomb retinal dystrophy. *Nat Genet* 1999 Jun; 22(2): 199-202.
307. Stur M: VER Study Group. Verteporfin Early Retreatment (VER) - 12-month results of a phase IIIB controlled clinical trial [E-]. *Invest Ophthalmol Vis Sci* 2004; 45: 2275.
308. Subasi M, Akmansu M, Or M: Treatment of age-related subfoveal neovascular membranes by teletherapy: results of a non-randomized study. *Radiat Med* 1999 Mar-Apr; 17(2): 169-73.
309. Sunness JS, Gonzalez-Baron J, Bressler NM, Hawkins B, Applegate CA. The development of choroidal neovascularization in eyes with the geographic atrophy form of age-related macular degeneration. *Ophthalmology*. 1999;106:910-919.

BIBLIOGRAPHY: Clinical Retina

310. Sunness JS, Rubin GS, Applegate CA, et al. Visual function abnormalities and prognosis in eyes with age-related geographic atrophy of the macula and good visual acuity. *Ophthalmology*. 1997;104:1677-1691.
311. Suter M, Reme C, Grimm C, et al. Age-related macular degeneration. The lipofuscin component n-retinyl-n-retinylidene ethanolamine detaches proapoptotic proteins from mitochondria and induces apoptosis in mammalian retinal pigment epithelial cells. *J Biol Chem*. 2000;275:39625-39630.
312. Takita H, Yoneya S, Gehlbach PL, et al: Retinal neuroprotection against ischemic injury mediated by intraocular gene transfer of pigment epithelium-derived factor. *Invest Ophthalmol Vis Sci* 2003 Oct; 44(10): 4497-504.
313. TAP Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. *Treatment of age-related macular degeneration with photodynamic therapy*. *Arch Ophthalmol* 1999 Oct; 117(10): 1329-45.
314. Teixeira A, Moraes N, Farah ME, Bonomo PP. Choroidal neovascularization treated with intravitreal injection of bevacizumab (Avastin) in angioid streaks. *Acta Ophthalmol Scand*. Dec 2006;84(6):835-6. .
315. Tewari A, Dhalla MS, Apte RS. Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia. *Retina*. Nov-Dec 2006;26(9):1093-4. .
316. Thach AB, Sipperley JO, Dugel PU, et al: Large-spot size transpupillary thermotherapy for the treatment of occult choroidal neovascularization associated with age-related macular degeneration. *Arch Ophthalmol* 2003 Jun; 121(6): 817-20.
317. The Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. *Arch Ophthalmol*. 2004;122:564-572.
318. Tholen AM, Meister A, Bernasconi PP, Messmer EP: [Radiotherapy for choroidal neovascularization in age-related macular degeneration. A pilot study using low-versus high-dose photon beam radiation]. *Ophthalmologie* 1998 Oct; 95(10): 691-8.
319. Thomas E, SnET2 Study Group: SnET2 photodynamic therapy for age-related macular degeneration: visual acuity efficacy outcomes from two parallel phase III trials [E-]. *Invest Ophthalmol Vis Sci* 2004; 45: 2214.
320. Thomas MA, Dickinson JD, Melberg NS, Ibanez HE, Dhaliwal RS. Visual results after surgical removal of subfoveal choroidal neovascular membranes. *Ophthalmology*. Aug 1994;101(8):1384-96. .
321. Thylefors B: A global initiative for the elimination of avoidable blindness. *Am J Ophthalmol* 1998 Jan; 125(1): 90-3.
322. Tielsch JM, Javitt JC, Coleman A, et al: The prevalence of blindness and visual impairment among nursing home residents in Baltimore. *N Engl J Med* 1995 May 4; 332(18): 1205-9.
323. Ting TD, Oh M, Cox TA, et al: Decreased visual acuity associated with cystoid macular edema in neovascular age-related macular degeneration. *Arch Ophthalmol* 2002 Jun; 120(6): 731-7.
324. Tolentino MJ, Brucker AJ, Fosnot J, et al: Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a

BIBLIOGRAPHY: Clinical Retina

- nonhuman primate, laser-induced model of choroidal neovascularization. *Retina* 2004 Feb; 24(1): 132-8.
325. Tolentino MJ, Husain D, Theodosiadis P, et al: Angiography of fluoresceinated anti-vascular endothelial growth factor antibody and dextrans in experimental choroidal neovascularization. *Arch Ophthalmol* 2000 Jan; 118(1): 78-84.
 326. Tomany SC, Klein R, Klein BE; Beaver Dam Eye Study. The relationship between iris color, hair color, and skin sun sensitivity and the 10-year incidence of age-related maculopathy: the Beaver Dam Eye Study. *Ophthalmology*. 2003;110:1526-1533.
 327. Treatment of age-related macular degeneration with photodynamic therapy (TAP) St: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. *Arch Ophthalmol* 1999 Oct; 117(10): 1329-45.
 328. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group; Chakravarthy U, Adamis AP, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. *Ophthalmology*. 2006;113:1508.e1-25.
 329. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2. *Am J Ophthalmol*. 2001;131:541-560.
 330. Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. *Retina*. 2005;25:119-134.
 331. Verteporfin Roundtable Participants. Guidelines for using verteporfin (visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. *Retina*. February/March 2005;25(2):119-134. .
 332. VIP Study Group: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization. *Am J Ophthalmol* 2001 May; 131(5): 541-60.
 333. Wang JJ, Jakobsen K, Smith W, Mitchell P. Five-year incidence of age-related maculopathy in relation to iris, skin or hair colour, and skin sun sensitivity: the Blue Mountains Eye Study. *Clin Experiment Ophthalmol*. 2003;31:317-321.
 334. Weinberger AW, Wolf S, Kube T, et al: [Radiation therapy of occult choroidal neovascularisation (CNV) in age-related macular degeneration (AMD)]. *Klin Monatsbl Augenheilkd* 1999 Feb; 214(2): 96-9.
 335. West SK, Rosenthal FS, Bressler NM, et al. Exposure to sunlight and other risk factors for age-related macular degeneration. *Arch Ophthalmol*. 1989;107:875-879.
 336. Westfall AC, Osborn A, Kuhl D, et al. Acute endophthalmitis incidence: intravitreal triamcinolone. *Arch Ophthalmol*. 2005;123:1075-1077.
 337. Wijnngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. *JAMA*. 2005;293:1509-1513.

BIBLIOGRAPHY: Clinical Retina

338. Wing GL, Blanchard GC, Weiter JJ. The topography and age relationship of lipofuscin concentration in the retinal pigment epithelium. *Invest Ophthalmol Vis Sci.* 1978;17:601-607.
339. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. *Prog Retin Eye Res.* 2003;22:1-29.
340. Wood CM, Richardson J. Chorioretinal neovascular membranes complicating contusional eye injuries with indirect choroidal ruptures. *Br J Ophthalmol.* Feb 1990;74(2):93-6. .
341. Wormald R, Evans J, Smeeth L, Henshaw K. Photodynamic therapy for neovascular age-related macular degeneration. *Cochrane Database Syst Rev.* 2003;(2):CD002030. .
342. Wu L, Murphy RP. Photodynamic therapy: a new approach to the treatment of choroidal neovascularization secondary to age-related macular degeneration. *Curr Opin Ophthalmol.* Jun 1999;10(3):217-20. .
343. Wyhinny GJ, Jackson JL, Jampol LM, Caro NC. Subretinal neovascularization following multiple evanescent white-dot syndrome. *Arch Ophthalmol.* Oct 1990;108(10):1384-5. .
344. Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. *Br J Ophthalmol.* Feb 2007;91(2):157-60. Epub 2006 Jul 26.
345. Yannuzzi LA, Negrao S, Iida T, Carvalho C, Rodriguez-Coleman H, Slakter J, Freund KB, Sorenson J, Orlock D, Borodoker N. Retinal angiomatous proliferation in age-related macular degeneration. *Retina* 2001;21(5):416-34.
346. Yi X, Ogata N, Komada M, et al: Vascular endothelial growth factor expression in choroidal neovascularization in rats. *Graefes Arch Clin Exp Ophthalmol* 1997 May; 235(5): 313-9.
347. Yonemoto LT, Slater JD, Friedrichsen EJ, et al: Phase I/II study of proton beam irradiation for the treatment of subfoveal choroidal neovascularization in age-related macular degeneration: treatment techniques and preliminary results. *Int J Radiat Oncol Biol Phys* 1996 Nov 1; 36(4): 867-71.
348. Young RW: Pathophysiology of age-related macular degeneration. *Surv Ophthalmol* 1987 Mar-Apr; 31(5): 291-306.
349. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. *Arch Ophthalmol.* 2004;122:598-614.

350. Diabetic Retinopathy

351. Adamis AP, Altaweel M, Bressler NM et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. *Ophthalmology* 113(1), 23-28 (2006).
352. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. *Am J Ophthalmol.* 1994;118:445-450.
353. Adamis AP. Is diabetic retinopathy an inflammatory disease? *Br. J. Ophthalmol.* 86(4), 363-365 (2002).

BIBLIOGRAPHY: Clinical Retina

354. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. *N Engl J Med.* 1994;331:1480-1487.
355. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. *Diabetes.* 1997;46:1473-1480.
356. Aiello LP, Davis MD, Girach A et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. *Ophthalmology* 113(12), 2221-2230 (2006).
357. Albert DM, Jakobiec FA: Principles and Practice of Ophthalmology. 2nd ed. Philadelphia: WB Saunders Co; 2000.
358. Avery RL, Pearlman J, Pieramici DJ et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. *Ophthalmology* 113(10), 1695-1705 (2006).
359. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. *Ophthalmology* 113(3), 363-372 (2006).
360. Avitabile T, Longo A, Reibaldi A: Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. *Am J Ophthalmol* 2005 Oct; 140(4): 695-702.
361. Bakri SJ, Kaiser PK. Posterior subtenon triamcinolone acetate for refractory diabetic macular edema. *Am J Ophthalmol.* 2005;139:290-294.
362. Bergerhoff K, Clar C, Richter B. Aspirin in diabetic retinopathy. A systematic review. *Endocrinol. Metab. Clin. North Am.* 31(3), 779-793 (2002).
363. Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. *Br. J. Ophthalmol.* 90, 1542-1547 (2006).
364. Boehm BO. Use of long-acting somatostatin analogue treatment in diabetic retinopathy. *Dev. Ophthalmol.* 39, 111-121 (2007).
365. Bonini-Filho MA, Jorge R, Barbosa JC, et al. Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetate for refractory diabetic macular edema: a randomized clinical trial. *Invest Ophthalmol Vis Sci.* 2005;46:3845-3849.
366. Bonini-Filho MA, Jorge R, Barbosa JC, et al: Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetate for refractory diabetic macular edema: a randomized clinical trial. *Invest Ophthalmol Vis Sci* 2005 Oct; 46(10): 3845-9.
367. Braun CI, Benson WE, Remaley NA, Chew EY, Ferris FL III, Early Treatment Diabetic Retinopathy Study Research Group: Accommodation amplitudes in the Early Treatment Diabetic Retinopathy Study. *ETDRS Report Number 21. Retina* 15: 275-281, 1995
368. Brown JC, Solomon SD, Bressler SB, et al. Detection of diabetic foveal edema: contact lens biomicroscopy compared with optical coherence tomography. *Arch Ophthalmol.* 2004;122:330-335.
369. Caldwell RB, Bartoli M, Behzadian MA et al. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. *Curr. Drug Targets* 6(4), 511-5124 (2005).

BIBLIOGRAPHY: Clinical Retina

370. Campochiaro PA; C99-PKC412-003 Study Group. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. *Invest Ophthalmol Vis Sci.* 2004;45:922-931.
371. Canataroglu H, Varinli I, Ozcan AA, et al. Interleukin (IL)-6, interleukin (IL)-8 levels and cellular composition of the vitreous humor in proliferative diabetic retinopathy, proliferative vitreoretinopathy, and traumatic proliferative vitreoretinopathy. *Ocul Immunol Inflamm.* 2005;13:375-381.
372. Cardillo JA, Melo LA Jr, Costa RA, et al. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. *Ophthalmology.* 2005;112:1557-1563.
373. Chew EY, Klein ML, Ferris FL 3rd, et al: Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. *Arch Ophthalmol* 1996 Sep; 114(9): 1079-84.
374. Chew EY, Klein ML, Ferris FL III, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. *Arch Ophthalmol.* 1996;114:1079-1084.
375. Chew EY, Klein ML, Ferris FL III, Remaley NA, Murphy RP, Chantry K, Hoogwerf BJ, Miller D, Early Treatment Diabetic Retinopathy Study Research Group: Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. ETDRS Report Number 22. *Arch Ophthalmol* 114: 1079-1084, 1996
376. Chew EY, Klein ML, Murphy RP, Remaley NA, Ferris FL III, Early Treatment Diabetic Retinopathy Study Research Group: Effects of aspirin on preretinal hemorrhage in patients with diabetes mellitus. ETDRS Report Number 20. *Arch Ophthalmol* 113: 52-55, 1995
377. Chew EY, Williams GA, Burton TC, Barton FB, Remaley NA, Ferris FL, Early Treatment Diabetic Retinopathy Study Research Group: Aspirin effects on the development of cataracts in patients with diabetes mellitus. ETDRS Report Number 16. *Arch Ophthalmol* 110: 339-342, 1992
378. Chibber R, Ben-Mahmud BM, Chibber S, Kohner EM. Leukocytes in diabetic retinopathy. *Curr. Diabetes Rev.* 3(1), 3-14 (2007).
379. Chieh JJ, Roth DB, Liu M, et al. Intravitreal triamcinolone acetonide for diabetic macular edema. *Retina* 2005;25:828-834.
380. Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. *Ophthalmology* 113(10), 1706-1712 (2006).
381. Chung SS, Chung SK. Aldose reductase in diabetic microvascular complications. *Curr. Drug Targets* 6(4), 475-86 (2005).
382. Clermont A, Bursell SE, Feener EP. Role of the angiotensin II Type 1 receptor in the pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond. *J. Hypertens. Suppl.* 24(1), S73-S80 (2006).
383. Cunningham ET Jr, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. *Ophthalmology.* 2005;112:1747-1757.

BIBLIOGRAPHY: Clinical Retina

384. Cunningham ET, Adamis AP, Altaweel M, et al: A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. *Ophthalmology* 2005 Oct; 112(10): 1747-57.
385. Diabetes Control and Complications Trial Research Group. The effect of intensive diabetic treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. *Arch Ophthalmol.* 1995;113:36-51.
386. Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study findings: DRS Report 8. *Ophthalmology.* 1981;88:583-600.
387. Early Treatment Diabetic Retinopathy Study Investigators: Aspirin effects on mortality and morbidity in patients with diabetes mellitus. *ETDRS Report 14. JAMA* 268: 1292-1300, 1992
388. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. *ETDRS Report 9. Ophthalmology.* 1991;98:766-785.
389. Early Treatment Diabetic Retinopathy Study Research Group: Classification of diabetic retinopathy from fluorescein angiograms. *ETDRS Report Number 11. Ophthalmology* 98: 807-822, 1991
390. Early Treatment Diabetic Retinopathy Study Research Group: Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. *ETDRS Report Number 7. Ophthalmology* 98: 741-756, 1991
391. Early Treatment Diabetic Retinopathy Study Research Group: Early photocoagulation for diabetic retinopathy. *ETDRS Report Number 9. Ophthalmology* 98: 766-785, 1991
392. Early Treatment Diabetic Retinopathy Study Research Group: Effects of aspirin treatment on diabetic retinopathy. *ETDRS Report Number 8. Ophthalmology* 98: 757-765, 1991
393. Early Treatment Diabetic Retinopathy Study Research Group: Fluorescein angiographic risk factors for progression of diabetic retinopathy. *ETDRS Report Number 13. Ophthalmology* 98: 834-840, 1991
394. Early Treatment Diabetic Retinopathy Study Research Group: Focal photocoagulation treatment of diabetic macular edema. *ETDRS Report Number 19. Arch Ophthalmol* 113: 1144-1155, 1995
395. Early Treatment Diabetic Retinopathy Study Research Group: Fundus photographic risk factors for progression of diabetic retinopathy. *ETDRS Report Number 12. Ophthalmology* 98: 823-833, 1991
396. Early Treatment Diabetic Retinopathy Study Research Group: Grading diabetic retinopathy from stereoscopic color fundus photographs: An extension of the modified Airlie House classification. *ETDRS Report Number 10. Ophthalmology* 98: 786-806, 1991
397. Early Treatment Diabetic Retinopathy Study Research Group: Photocoagulation for diabetic macular edema. *Early Treatment Diabetic Retinopathy Study Report Number 4. Int Ophthalmol Clin* 27: 265-272, 1987
398. Early Treatment Diabetic Retinopathy Study Research Group: Techniques for scatter and local photocoagulation treatment of diabetic retinopathy. *Early*

BIBLIOGRAPHY: Clinical Retina

399. Early Treatment Diabetic Retinopathy Study Research Group: Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. *Ophthalmology* 94: 761-774, 1987
400. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. The Diabetic Retinopathy Vitrectomy Study Research Group. *Arch Ophthalmol.* 1985;103:1644-1652.
401. Eter N, Spaide RF. Comparison of fluorescein angiography and optical coherence tomography for patients with choroidal neovascularization after photodynamic therapy. *Retina.* 2005;25:691-696.
402. Ferris FL III, Chew EY, Hoogwerf BJ, Early Treatment Diabetic Retinopathy Study Research Group: Serum lipids and diabetic retinopathy. *Diabetes Care* 19: 1291-1293, 1996
403. Ferris FL III, Patz A. Macular edema. A complication of diabetic retinopathy. *Surv Ophthalmol.* 1984;28:452-461.
404. Ferris FL III: Early photocoagulation in patients with either type 1 or type II diabetes. *Tr Am Ophth Soc* 94: 505-537, 1996
405. Ferris FL III: How effective are treatments for diabetic retinopathy? (commentary). *JAMA* 269: 1290-1291, 1993
406. Fletcher EL, Phipps JA, Wilkinson-Berka JL. Dysfunction of retinal neurons and glia during diabetes. *Clin. Exp. Optom.* 88(3), 132-145 (2005).
407. Flynn HW, Chew EY, Simmons BD, Barton FB, Remaley NA, Ferris FL, Early Treatment Diabetic Retinopathy Study Research Group: Pars Plana Vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS Report Number 17. *Ophthalmology* 99: 1351-1357, 1992
408. Fong DS, Barton FB, Bresnick GH, ETDRS Research Group: Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study (ETDRS Report No. 15.) *Am J Ophthalmol* 128: 612-617, 1999
409. Fong DS, Ferris FL, Davis MD, Chew EY, ETDRS Research Group: Causes of severe visual loss in the Early Treatment Diabetic Retinopathy Study (ETDRS Report No. 24.) *Am J Ophthalmol* 127: 137-141, 1999
410. Fong DS, Segal PP, Myers F, et al: Subretinal fibrosis in diabetic macular edema. ETDRS report 23. Early Treatment Diabetic Retinopathy Study Research Group. *Arch Ophthalmol* 1997 Jul; 115(7): 873-7.
411. Frank RN. Diabetic retinopathy. *N. Engl. J. Med.* 350(1), 48-58 (2004).
412. Funatsu H, Yamashita H, Ikeda T, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. *Ophthalmology.* 2003;110:1690-1696.
413. Funatsu H, Yamashita H, Nakamura S, et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. *Ophthalmology.* 2006;113:294-301.
414. Funatsu H, Yamashita H. Pathogenesis of diabetic retinopathy and the renin-angiotensin system. *Ophthalmic Physiol. Opt.* 23(6), 495-501 (2003).

BIBLIOGRAPHY: Clinical Retina

415. Gao BB, Clermont A, Rook S et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. *Nat. Med.* 13(2), 181-188 (2007).
416. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. *Ophthalmology* 113(9), 1533-1538 (2006).
417. Girach A, Manner D, Porta M. Diabetic microvascular complications: can patients at risk be identified? A review. *Int. J. Clin. Pract.* 60(11), 1471-1483 (2006).
418. Goebel W, Franke R. Retinal thickness in diabetic retinopathy: comparison of optical coherence tomography, the retinal thickness analyser and fundus photography. *Retina* 2006;26:49-57.
419. Hammes HP, Du X, Edelstein D et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. *Nat. Med.* 9(3), 294-299 (2003).
420. Heimann, H et al, Atlas of Fundus Angiography, Stuggart: Thieme, 2006.
421. Idris I, Donnelly R. Protein kinase C β inhibition: a novel therapeutic strategy for diabetic microangiopathy. *Diab. Vasc. Dis. Res.* 3(3), 172-178 (2006).
422. International Diabetes Federation. Diabetes prevalence.
423. Jaffe GJ. Update on pharmacologic treatment of diabetic macular edema. *Retina Today* 2, 49-54 (2006).
424. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreal injection: a comprehensive review. *Retina* 24(5), 676-698 (2004).
425. Jain A, Sarraf D, Fong D. Preventing diabetic retinopathy through control of systemic factors. *Curr. Opin. Ophthalmol.* 14(6), 389-394 (2003).
426. Jonas JB, Degenring RF, Kampeter BA, et al. Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema. *Am J Ophthalmol.* 2004;138:158-160.
427. Jonas JB, Harder B, Kampeter BA. Inter-eye difference in diabetic macular edema after unilateral intravitreal injection of triamcinolone acetonide. *Am J Ophthalmol.* 2004;138:970-977.
428. Jonas JB, Martus P, Degenring RF, et al: Predictive factors for visual acuity after intravitreal triamcinolone treatment for diabetic macular edema. *Arch Ophthalmol* 2005 Oct; 123(10): 1338-43.
429. Jonas JB. Intravitreal triamcinolone acetonide for diabetic retinopathy. *Dev. Ophthalmol.* 39, 96-110 (2007).
430. Jousseaume AM, Poulaki V, Le ML et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. *FASEB J.* 18(12), 1450-1452 (2004).
431. Jousseaume AM, Poulaki V, Mitsiades N et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-suppression. *FASEB J.* 16(3), 438-440 (2002).
432. Kempen JH, O'Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. *Arch Ophthalmol.* 2004;122:552-563.
433. Kertes: Clinical Trials in Ophthalmology: Summary and Practice Guide. Lippincott Williams & Wilkins; 1998:15-35.

BIBLIOGRAPHY: Clinical Retina

434. Kinyoun J, Barton F, Fisher M, Hubbard LL, Aiello L, Ferris FL III, Early Treatment Diabetic Retinopathy Study Research Group: Detection of diabetic macular edema. Ophthalmoscopy versus photography. ETDRS Report Number 5. *Ophthalmology* 69: 746-751, 1989
435. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. *Ophthalmology*. 1984;91:1464-74.
436. Klein R, Klein BEK. Vision disorders in diabetes. In: Harris MI, Cowie CC, Stern MP, et al., eds. *Diabetes in America*. Bethesda, Md: National Diabetes Data Group, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995; NIH Publication no. 95-1468.
437. Kohner EM. Aspirin for diabetic retinopathy. *Br. Med. J.* 327(7423), 1060-1061 (2003).
438. Krady JK, Basu A, Allen CM et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. *Diabetes* 54(5), 1559-1565 (2005).
439. Kristinsson JK, Stefansson E, Jonasson F, et al. Systematic screening for diabetic eye disease in insulin dependent diabetes. *Acta Ophthalmol.* 1994;72:72-78.
440. Krogsaa B, Lund-Andersen H, Mehlsen J, et al. The blood-retinal barrier permeability in diabetic patients. *Acta Ophthalmol (Copenh)*. 1981;59:689-694.
441. Kuppermann BD, Blumenkranz MS, Haller JA et al. Randomized controlled study of an intravitreal dexamethasone drug delivery system in patients with persistent macular edema. *Arch. Ophthalmol.* 125(3), 309-317 (2007).
442. Kuppermann BD, Thomas EL, de Smet MD, Grillone LR. Vitrase for Vitreous Hemorrhage Study Groups. Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreal injection of highly purified ovine hyaluronidase (Vitrax) for the management of vitreous hemorrhage. *Am. J. Ophthalmol.* 140(4), 573-584 (2005).
443. Kuppermann BD, Thomas EL, de Smet MD, Grillone LR. Vitrase® for Vitreous Hemorrhage Study Groups. Safety results of two Phase III trials of an intravitreal injection of highly purified ovine hyaluronidase (Vitrax®) for the management of vitreous hemorrhage. *Am. J. Ophthalmol* 140(4), 585-597 (2005).
444. Kuppermann BD, Williams GA, Blumenkranz MS, et al. Efficacy and safety of a novel intravitreal dexamethasone drug-delivery system after applicator or incisional placement in patients with macular edema. Program and s of the Association for Research in Vision and Ophthalmology; April 30-May 4, 2006; Fort Lauderdale, Florida.
445. Kylstra JA, Brown JC, Jaffe GJ, et al. The importance of fluorescein angiography in planning laser treatment of diabetic macular edema. *Ophthalmology*. 1999;106:2068-2073.
446. Lam DS, Chan CK, Mohamed S et al. A prospective randomized trial of different doses of intravitreal triamcinolone for diabetic macular oedema. *Br. J. Ophthalmol.* 91(2), 199-203 (2007).
447. Lang GE. Laser treatment of diabetic retinopathy. *Dev. Ophthalmol.* 39, 48-68 (2007).
448. Lang GE. Treatment of diabetic retinopathy with protein kinase C subtype B inhibitor. *Dev. Ophthalmol.* 39, 157-165 (2007).

BIBLIOGRAPHY: Clinical Retina

449. Leibovitch I, Loewenstein A, Alster Y, et al. Interferon alpha-2a for proliferative diabetic retinopathy after complete laser panretinal photocoagulation treatment. *Ophthalmic Surg Lasers Imaging*. 2004;35:16-22.
450. Lewis H. Role of vitrectomy in the treatment of diabetic macular edema. *Am. J. Ophthalmol.* 131(1), 123-125 (2001).
451. Liu H, Ren JG, Cooper WL. Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. *Proc Natl Acad Sci USA*. 2004;101:6605-6610.
452. Lu M, Kuroki M, Amano S, et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. *J Clin Invest*. 1998;101:1219-1224.
453. Luttrull JK, Musch DC, Mainster MA. Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema. *Br. J. Ophthalmol.* 89(1), 74-80 (2005).
454. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. *Ophthalmology*. 2002;109:920-927.
455. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. *Ophthalmology*. 2004;111:218-224.
456. Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM. Risk of progression of retinopathy and visual loss related to tight control of blood pressure in Type 2 diabetes mellitus. UKPDS 69. *Arch. Ophthalmol.* 122(11), 1631-1640 (2004).
457. Neubauer AS, Ulbig MW. Laser treatment in diabetic retinopathy. *Ophthalmologia* 221(2), 95-102 (2007).
458. Ng EW, Adamis AP. Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. *Ann. NY Acad. Sci.* 1082, 151-171 (2006).
459. Nguyen QD, Shah SM, Van Anden E, et al. Supplemental oxygen improves diabetic macular edema: a pilot study. *Invest Ophthalmol Vis Sci*. 2004;45:617-624.
460. Otani T, Kishi S, Maruyama Y: Patterns of diabetic macular edema with optical coherence tomography. *Am J Ophthalmol* 1999 Jun; 127(6): 688-93.
461. Otani T, Kishi S. A controlled study of vitrectomy for diabetic macular edema. *Am J Ophthalmol*. 2002;134:214-219.
462. Palii SS, Caballero S Jr, Shapiro G, Grant MB. Medical treatment of diabetic retinopathy with somatostatin analogues. *Expert Opin. Investig. Drugs* 16(1), 73-82 (2007).
463. Patel JI, Jykin PG, Schadt M, et al. Pars plana vitrectomy with and without peeling of the internal limiting membrane for diabetic macular edema. *Retina*. 2006;26:5-13.
464. Patelli F, Fasolino G, Radice P, et al: Time course of changes in retinal thickness and visual acuity after intravitreal triamcinolone acetonide for diffuse diabetic macular edema with and without previous macular laser treatment. *Retina* 2005 Oct-Nov; 25(7): 840-5.
465. Pearson P, Levy B; Fluocinolone Acetonide Implant Study Group. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 2-year results of a

BIBLIOGRAPHY: Clinical Retina

- multi-center clinical trial. Program and s of the Association for Research in Vision and Ophthalmology 2005 Annual Meeting, FL, USA (2005) (4673).
466. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 1. *Arch Ophthalmol* 103: 1796, 1985
 467. Pomeroy F, Allione A, Beltramo E et al. Effects of protein kinase C inhibition and activation on proliferation and apoptosis of bovine retinal pericytes. *Diabetologia* 46(3), 416-419 (2003).
 468. Prior MJ, Prout T, Miller D, Ewart R, Kumar D, Early Treatment Diabetic Retinopathy Research Group: C-peptide and the classification of diabetes patients in the Early Treatment Diabetic Retinopathy Study. ETDRS Report Number 6. *Ann Epidemiol* 3: 9-17, 1993
 469. Quresh M, et al: Management of Diabetic Retinopathy: A Systematic Review *JAMA*. 2007;298(8):902-916.
 470. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. *Ophthalmic Surg. Lasers Imaging* 36(4), 331-335 (2005).
 471. Saishin Y, Saishin Y, Takahashi K, et al. Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier. *J Cell Physiol*. 2003;195:210-219.
 472. Sakuma T, Tanaka M, Mizota A et al. Safety of in vivo pharmacologic vitreolysis with recombinant microplasmin in rabbit eyes. *Invest. Ophthalmol. Vis. Sci.* 46(9), 3295-3299 (2005).
 473. Sakuraba T, Suzuki Y, Mizutani H, et al. Visual improvement after removal of submacular exudates in patients with diabetic maculopathy. *Ophthalmic Surg Lasers*. 2000;31:287-291.
 474. Sandu SS, Birch MK, Griffiths PG et al. Short-term effects of focalargon laser treatment in diabetic maculopathy as demonstrated by optical coherence tomography. *Retina* 2007;27:13-20.
 475. Setter SM, Campbell RK, Cahoon CJ. Biochemical pathways for microvascular complications of diabetes mellitus. *Ann. Pharmacother.* 37(12), 1858-1866 (2003).
 476. Shah SP, Patel M, Thomas D, et al. Factors predicting outcome of vitrectomy for diabetic macular oedema: results of a prospective study. *Br J Ophthalmol*. 2006;90:33-36.
 477. Shams N, Ianchulev T. Role of vascular endothelial growth factor in ocular angiogenesis. *Ophthalmol. Clin. North Am.* 19(3), 335-344 (2006).
 478. Sherris D. Ocular drug development - future directions. *Angiogenesis* 10(2), 71-76 (2007).
 479. Sheth HG, Aslam S, Davies N. Lipid lowering drugs in diabetes: lipid lowering has ophthalmic benefits. *Br. Med. J.* 332(7552), 1272-1273 (2006).
 480. Sjolie AK, Porta M, Parving HH, Bilous R, Klein R. The DIRECT Programme Study Group. The Diabetic Retinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics. *J. Renin Angiotensin Aldosterone Syst.* 6(1), 25-32 (2005).
 481. Sjolie AK. Prospects for angiotensin receptor blockers in diabetic retinopathy. *Diabetes Res. Clin. Pract.* 76(Suppl. 1), S31-S39 (2007).

BIBLIOGRAPHY: Clinical Retina

482. Soomro, H, Burnett L, Davies N Quantifying Changes in Retinal Anatomy After Interventions for Diabetic Maculopathy *Br J Diabetes Vasc Dis.* 2007;7(4):181-185.
483. Strom C, Sander B, Klemp K, et al. Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema. *Invest Ophthalmol Vis Sci.* 2005;46:3855-3858.
484. Sun W, Oates PJ, Coutcher JB, Gerhardinger C, Lorenzi M. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. *Diabetes* 55(10), 2757-2762 (2006).
485. Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. *Ophthalmology.* 2004;111:2044-2049.
486. Tachi N, Ogino N: Vitrectomy for diffuse macular edema in cases of diabetic retinopathy. *Am J Ophthalmol* 1996 Aug; 122(2): 258-60.
487. Takagi H, Otani A, Kiryu J, Ogura Y: New surgical approach for removing massive foveal hard exudates in diabetic macular edema. *Ophthalmology* 1999 Feb; 106(2): 249-56; discussion 256-7.
488. Takaya K, Suzuki Y, Mizutani H, et al. Long-term results of vitrectomy for removal of submacular hard exudates in patients with diabetic maculopathy. *Retina.* 2004;24:23-29.
489. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N. Engl. J. Med.* 329(14), 977-986 (1993).
490. The PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. *Diabetes.* 2005;54:2188-2197.
491. The UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet.* 1998;352:837-853.
492. Trese MT. Enzymatic-assisted vitrectomy. *Eye* 16(4), 365-368 (2002).
493. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38), *BMJ.* 1998;317:703-713.
494. UKPDS Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). *UK Prospective Diabetes Study (UKPDS) Group. Lancet* 352(9131), 837-853 (1998).
495. Wada M, Ogata N, Minamino K, et al. Trans-tenon's retrobulbar injection of triamcinolone acetonide for diffuse diabetic macular edema. *Jpn J Ophthalmol.* 2005;49:509-515.

BIBLIOGRAPHY: Clinical Retina

496. Wilkinson CP, Ferris FL, Klein RE et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. *Ophthalmology* 110(9), 1677-1682 (2003).
497. Wilkinson-Berka JL, Wraight C, Werther G. The role of growth hormone, insulin-like growth factor and somatostatin in diabetic retinopathy. *Curr. Med. Chem.* 13(27), 3307-3317 (2006).
498. Wilkinson-Berka JL. Angiotensin and diabetic retinopathy. *Int. J. Biochem. Cell Biol.* 38(5-6), 752-765 (2006).
499. Yang JC, Haworth L, Sherry RM et al. Randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. *N. Engl. J. Med.* 349(5), 427-434 (2003).
500. Yi Q, Bamroongsuk P, McCarty DJ, Mukesh BN, Harper CA. Clinical outcomes following laser photocoagulation treatment for diabetic retinopathy at a large Australian ophthalmic hospital. *Clin. Experiment. Ophthalmol.* 31(4), 305-309 (2003).
501. Zheng L, Howell SJ, Hatala DA, Huang K, Kern TS. Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. *Diabetes* 56(2), 337-345 (2007)

502. CME

503. Aaberg TM. Pars plana vitrectomy for persistent aphakic cystoid macular edema secondary to vitreous incarceration in the cataract wound. In: McPherson A, ed. *New and Controversial Aspects of Vitrectomy Surgery*. St Louis: Mosby; 1977:230-239.
504. Abe T, Hayasaka S, Nagaki Y, et al: Pseudophakic cystoid macular edema treated with high-dose intravenous methylprednisolone. *J Cataract Refract Surg* 1999 Sep; 25(9): 1286-8.
505. Ahad MA, McKee HDR. Stopping prostaglandin analogues in uneventful cataract surgery. *J Cataract Refract Surg.* 2004;30:2644-2645.
506. Ah-Fat FG, Sharma MK, Majid MA, Yang YC. Vitreous loss during conversion from conventional extracapsular cataract extraction to phacoemulsification. *J Cataract Refract Surg.* 1993;24:801-805.
507. Allen AW, Jaffee NS. Cystoid macular edema-A preliminary study. *Trans Am Acad Ophthalmol Otolaryngol* 1976;81:133-134.
508. Alpar JJ. Diabetes: Cataract extraction and intraocular lens. *J Cataract Refract Surg* 1987;13:43-46.
509. Alpar JJ. Keratoplasty with primary and secondary lens implantation. *Ophthalmic Surg* 1978;9:58-66.
510. Altintas O, Yuksel N, Karabas VL: Cystoid macular edema associated with latanoprost after uncomplicated cataract surgery. *Eur J Ophthalmol* 2005; 15(1): 158-61.
511. Apple DJ, Mamalis N, Lofffield K, et al. Complications of intraocular lenses. A historical and histopathological review. *Surv Ophthalmol* 1984;29:1-54.

BIBLIOGRAPHY: Clinical Retina

512. Arcieri ES, Santana A, Rocha FN, et al. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial. *Arch Ophthalmol*. 2005;123:186-192.
513. Aron-Rosa D, ed. *Pulsed YAG Laser Surgery*. Thorofare, NJ: Charles Slack; 1983:30,53.
514. Baltazis S, Theodossiadis G, Velissaropoulos P. Irvine-Gass syndrome. Statistical and angiographic study. *Arch Ophthalmol (Paris)* 1976;36:21-32.
515. Behrens-Baumann W, Quentin CD, Eckhardt B, et al. Grading and evaluating cystoid macular edema. *Klin Monatsbl Augenheilkd* 1989;194:16-21.
516. Benhamou N, Massin P, Haouchine B. Intravitreal triamcinolone for refractory pseudophakic macular edema. *Am J Ophthalmol*. 2003;135:246-249.
517. Berger BB, Zweig KO, Peyman GA. Vitreous loss managed by anterior vitrectomy. *Arch Ophthalmol* 1980;98:1245-1247.
518. Bergman M, Laatikainen L. Cystoid macular oedema after complicated cataract surgery and implantation of an anterior chamber lens. *Acta Ophthalmologica* 1994; 72:178-180.
519. Berrocal JAR. Incidence of cystoid macular edema after cataract operations. *Mod Probl Ophthalmol* 1977;18:518-520.
520. Binkhorst CD, Leonard PAM. Results in 208 iris-clip pseudophakos implantations. *Am J Ophthalmol* 1967;64:947-956.
521. Binkhorst CD. Comeal and retinal complications after cataract extraction: The mechanical aspect of endophthalmodonesis. *Ophthalmology* 1980;87:609-617.
522. Bito LZ. Prostaglandins: Old concepts and new perspectives. *Arch Ophthalmol* 1987;105:1036-1039.
523. Boniuk M. Cystic macular edema secondary to vitreoretinal traction. *Surv Ophthalmol* 1968;13:118-121.
524. Bonnet M, Bievez B. Fluorescein angiography of the iris and Irvine-Gass syndrome (selection of indications for anterior vitrectomy) *Bull Soc Ophthalmol Fr* 1981;81:1001-1003.
525. Bonnet M, Bievez B. Iris fluorescein angiography and Irvine-Gass syndrome. *Graefes Arch Klin Exp Ophthalmol* 1980;213:187-194.
526. Bonnet M, Grange JD, Pingault C. Frequency of macular edema after cataract extraction. *Ann Ocul (Paris)* 1975;208:217-220.
527. Bonnet M. Factors of prognosis in the Irvine-Gass syndrome. *Ann Ocul (Paris)* 1975;208:275-278.
528. Bonnet M. The Irvine-Gass syndrome. *Arch Ophthalmol (Paris)* 1972;32:705-720.
529. Bovino JA, Kelly TJ, Marcus DF. Intraretinal hemorrhages in cystoid macular edema *Arch Ophthalmol* 1984;102:1151-1152.
530. Bradford JD, Wilkinson CP, Bradford RH. Cystoid macular edema following extracapsular cataract extraction and posterior chamber intraocular lens implantation. *Retina* 1988;8:161-164.
531. Brownstein S, Orton R, Jackson BW. Cystoid macular edema with equatorial choroidal melanoma. *Arch Ophthalmol* 1978;96:2105-2107.
532. Campo RV, Sipperley JO, Sneed SR, et al. Pars plana vitrectomy without scleral buckle for pseudophakic retinal detachments. *Ophthalmology*. 1999;106:1811-1815.

BIBLIOGRAPHY: Clinical Retina

533. Catier A, Tadayoni R, Paques M, et al. Characterization of Macular Edema From Various Etiologies by Optical Coherence Tomography. *Am Jo Ophthal* August 2005 (Vol. 140, Issue 2
534. Chambless WS. Phacoemulsification and the retina: Cystoid macular edema. *Trans Am Acad Ophthalmol Otolaryngol* 1979;86:2019-2023.
535. Chandler PA. Complications after cataract extraction:clinical aspects. *Trans Am Acad Ophthalmol Otolaryngol* 1954;58:382-396.
536. Chen JC, Fitzke FW, Bird AC. Long-term effect of acetazolamide in a patient with retinitis pigmentosa. *Invest Ophthalmol Vis Sci* 1990;31:1914-1918.
537. Ching HY, Wong AC, Wong CC: Cystoid macular oedema and changes in retinal thickness after phacoemulsification with optical coherence tomography. *Eye* 2005; 8.
538. Chopdar A. Annular choroidal sclerosis. *BrJ Ophthalmol* 1976;60:512-516.
539. Cleary PE, Leaver PK. Macular abnormality in the reattached retina. *BrJ Ophthalmol* 1978;62:595-601.
540. Cleasby GW. Vitreous surgery as a supplement to cataract surgery. *Ann Ophthalmol* 1980;12:1200-1207.
541. Cogan DG, Guzak SV. Fluoroangiographic pattern of macular edema and retinal swelling in postmortem eyes. *AmJ Ophthalmol* 1971;71:291-297.
542. Collins JF, Krol WF, Kirk GF, Gaster RN; VA Cooperative Cataract Study Group. The effect of vitreous presentation during extracapsular cataract surgery on the postoperative visual acuity at one year. *Am J Ophthalmol*. 2004;138:536-542.
543. Cox SN, Hay E, Bird AC. Treatment of chronic macular edema with acetazolamide. *Arch Ophthalmol* 1988;106:1190-1195.
544. Cunha-Vaz JG, Travessos A. Breakdown of the blood-retinal barriers and cystoid macular edema. *Survey Ophthalmol* 1984;28:485-492.
545. Cunliffe IA, Flanagan DW, George NDL, et al. Extracapsular cataract surgery with lens implantation in diabetics with and without proliferative retinopathy. *Br J Ophthalmol* 1991;75:9-12.
546. Dellaporte A. Fundus changes in postoperative hypotony. *Am J Ophthalmol* 1955;40:781-789.
547. Desai P. The national cataract surgery survey: II. Clinical outcomes. *Eye* 1993; 7:489-494.
548. Dick II JSB, Jampol LM, Haller JA. Macular edema. In: Ryan SJ, ed. *Retina*. St. Louis, MO: Mosby; 2001: 967-981.
549. Drews RC. The present understanding of cystoid macular edema. *Trans Ophthalmol Soc UK* 1985;104:744-747.
550. Dugel PU, Rao NA, Ozler S, et al. Pars plana vitrectomy for intraocular inflammation related cystoid macular edema unresponsive to corticosteroids: A preliminary study. *Ophthalmology* 1992;99:1535-1541.
551. Easty D, Dallas N, O'Malley R. Aphakic macular oedema following prosthetic lens implantation. *BrJ Ophthalmol* 1977;61:321-326.
552. Epstein DL. Cystoid macular edema occurring 13 years after cataract extraction. *AmJ Ophthalmol* 1977;83:501-503.

BIBLIOGRAPHY: Clinical Retina

553. Evereklioglu C, Er H, Bekir NA, et al. Comparison of secondary implantation of flexible open-loop anterior chamber and scleral-fixated posterior chamber intraocular lenses. *J Cataract Refract Surg.* 2003;29:301-308.
554. Farber MD, Lam S, Tessler HH, et al. Reduction of macular oedema by acetazolamide in patients with chronic iridocyclitis: A randomised prospective crossover study. *Br J Ophthalmol* 1994;78:4-7.
555. Federman JL, Annesley WH, Sarin LK, et al. Vitrectomy and cystoid macular edema. *Ophthalmology* 1980;87:622-628.
556. Federman JL, Annesley WH Jr, Samin LK, et al. Vitrectomy and cystoid macular edema. *Ophthalmology* 1980;87:622-628.
557. Feldman RB, Mayo SS, Robertson DM, et al. Epiretinal membranes and cystoid macular edema in gyrate atrophy of the choroid and retina. *Retina* 1989;9:139-142.
558. Ferguson VMG, Spalton DJ. Continued breakdown of the blood aqueous barrier following cataract surgery. *Br J Ophthalmol* 1992;76:453-456.
559. Ferrari TM, Cavallo M, Durante G, et al. Macular edema induced by phacoemulsification. *Doc Ophthalmol.* 1999;97:325-327.
560. Ffytche TJ, Blach RK. The aetiology of macular oedema. *Trans Ophthalmol Soc UK* 1970;90:637-656.
561. Fine BS, Brucker AJ. Macular edema and cystoid macular edema. *Am J Ophthalmol* 1981;92:466-481.
562. Fishman et al. Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa. *Arch Ophthalmol* 1989; 107:1445-52.
563. Fishman GA, Gilbert LD, Fiscella RG, et al. Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa. *Arch Ophthalmol* 1989;107:1445-1452.
564. Fishman GA, Jampol LM, Goldberg MF. Diagnostic features of the Favre-Goldmann syndrome. *Br J Ophthalmol* 1976;60:345-353.
565. Flach AJ, Dolan BJ, Irvine AR. Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. *Am J Ophthalmol* 1987;103:479-486.
566. Flach AJ, Graham J, Kruger LP, et al. Quantitative assessment of postsurgical breakdown of the blood-aqueous barrier following administration of 0.5% ketorolac tromethamine solution. A double-masked, paired comparison with vehicle-placebo solution study. *Arch Ophthalmol* 1988;106:344-347.
567. Flach AJ, Jaffe NS, Akers WA, et al. The effect of ketorolac 0.5% solution in reducing postoperative inflammation: Double-mask, parallel comparison with dexamethasone phosphate 0.1% solution. *Ann Ophthalmol* 1989;21:407-411.
568. Flach AJ, Jampol LM, Weinberg D, et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. *Am J Ophthalmol* 1991 Nov 15; 112(5): 514-9.
569. Flach AJ, Kraff MC, Sanders DR, et al. The quantitative effect of 0.5% ketorolac tromethamine solution and dexamethasone phosphate 0.1% solution on postsurgical blood-aqueous barrier. *Arch Ophthalmol* 1988;106:480-483.
570. Flach AJ, Lavelle CJ, Olander KW, et al. The effect of ketorolac 0.5% solution in reducing postsurgical inflammation following extracapsular cataract extraction with

BIBLIOGRAPHY: Clinical Retina

- an intraocular lens: Double-masked, parallel comparison with vehicle. *Ophthalmology* 1988;75:1279-1284.
571. Flach AJ, Stegman RC, Graham J, et al. Prophylaxis of aphakic cystoid macular edema without corticosteroids. A paired comparison, placebo controlled double-masked study. *Ophthalmology* 1990;97:1253-1258
572. Flach AJ. Cyclo-oxygenase inhibitors in ophthalmology. *Surv Ophthalmol* 1992;36:259-284.
573. Flach AJ. Factors associated with improvement in vision during treatment of cystoid macular edema following cataract surgery. *Invest Ophthalmol Vis Sci* 1993;34:2285.
574. Flach AJ. Nonsteroidal anti-inflammatory drugs in ophthalmology. *Int Ophthalmol Clin* 1993;33:1-7.
575. Flach AJ. Ophthalmic treatment of postoperative inflammation. *J Toxicol Cut Ocular Toxicol* 1991;10:253-277.
576. Flach AJ. Topical acetazolamide and other carbonic anhydrase inhibitors in the medical therapy of the glaucomas. *Glaucoma* 1986;8:20-27.
577. Francois J, Verbraeken H. Complications in 1,000 consecutive intracapsular cataract extractions. *Ophthalmologica* 1980;180:121-128.
578. Freedman J, Jordan AJ, Kokoris N. Cystoid macular edema in aphakic black patients. *Ann Ophthalmol* 1979;11:1699-1701.
579. Frost NA, Sparrow JM, Strong NP, et al. Vitreous loss in planned extracapsular cataract extraction does lead to a poorer visual outcome. *Eye*. 1995;9:446-451.
580. Frost NA, Sparrow JM, Strong NP, et al. Vitreous loss in planned extracapsular cataract extraction does lead to a poorer visual outcome. *Eye* 1995;9:446-451.
581. Fung WE, Vitrectomy-ACME Study Group. Vitrectomy for chronic aphakic cystoid macular edema. Results of a national, collaborative, prospective, randomized investigation. *Ophthalmology* 1985;92:1102-1111.
582. Fung WE. Anterior vitrectomy for chronic aphakic cystoid macular edema. *Ophthalmology* 1980;87:189-193.
583. Fung WE. Aphakic cystoid macular edema. In: Ryan SJ, Schachat AP, Murphy RB, Patz A, eds. *Retina*. St Louis: Mosby; 1989:767-779.
584. Fung WE. Surgical therapy for chronic aphakic cystoid macular edema. *Ophthalmology* 1982;89:898-901.
585. Fung WE. The national, prospective, randomized vitrectomy study for chronic aphakic cystoid macular edema. Progress report and comparison between the control and nonrandomized groups. *Surv Ophthalmol* 1984;28:569-576.
586. Fung WE: Vitrectomy for chronic aphakic cystoid macular edema. Results of a national, collaborative, prospective, randomized investigation. *Ophthalmology* 1985 Aug; 92(8): 1102-11.
587. Fung WF. Cystoid macular edema (CME, cystoid maculopathy, Irvine-Gass syndrome). In: Fraunfelder FT, Roy FH, Meyer SM, eds *Current Ocular Therapy*. Philadelphia: Saunders; 1990:624-627.
588. Ganesh SK, Babu K, Biswas J. Phacoemulsification with intraocular lens implantation in cases of pars planitis. *J Cataract Refract Surg*. 2004;30:2072-2076.
589. Gartner S. Optic neuritis and macular edema following cataract extraction. *Eye Ear Nose Throat Monthly* 1964;43:45-49.

BIBLIOGRAPHY: Clinical Retina

590. Gass JD, Norton EW: Cystoid macular edema and papilledema following cataract extraction. A fluorescein fundoscopic and angiographic study. Arch Ophthalmol 1966 Nov; 76(5): 646-61.
591. Gass JD, Norton EW: Fluorescein studies of patients with macular edema and papilledema following cataract extraction. Trans Am Ophthalmol Soc 1966; 64: 232-49.
592. Gass JD, Norton EW: Follow-up study of cystoid macular edema following cataract extraction. Trans Am Acad Ophthalmol Otolaryngol 1969 Jul-Aug; 73(4): 665-82.
593. Gass JD. A fluorescein angiographic study of macular dysfunction secondary to retinal vascular disease. II. Retinal vein obstruction. Arch Ophthalmol 1968;80:550.0
594. Gass JDM, Anderson DR, Davis EB. A clinical fluorescein angiographic and electron microscopic correlation of cystoid macular edema. AmJ Ophthalmol 1985;100:82-86.
595. Gass JDM, Norton EWD. Cystoid macular edema and papilledema following cataract extraction. Arch Ophthalmol 1966; 76:646-661.
596. Gass JDM, Norton EWD. Fluorescein studies of patients with macular edema and papilledema following cataract extraction. Trans Am Ophthalmol Soc 1966; 64:232-249.
597. Gass JDM, Norton EWD. Follow-up study of cystoid macular edema following cataract extraction. Trans Am Acad Ophthalmol Otolaryngol 1969;73:665-682.
598. Gass JDM. Lamellar holes: A complication of cystoid macular edema after cataract extraction. A clinicopathologic case report. Trans Am Ophthalmol Soc 1975;73:231-250.
599. Gass JDM. Stereoscopic Atlas of Macular Diseases. St Louis: Mosby; 1987:368-380.
600. Gehring JR. Macular edema following cataract extraction. Arch Ophthalmol 1968;80:626-631.
601. Gilbard SM, Peyman GA, Goldberg MF Evaluation for cystoid maculopathy after pars plicata lensectomy-vitreotomy for congenital cataracts. Ophthalmology 1983;90:1201-1206.
602. Ginsburg AP, Cheetham JK, De Gryse RE, et al. Effects of flurbiprofen and indomethacin on acute cystoid macular edema after cataract surgery: Functional vision and contrast sensitivity. J Cataract Refract Surg 1995;21:82-92.
603. Goldberg I, Kolker AE, Kass MA, et al. Dipivefrin: Current concepts. Aust J Ophthalmol 1980;8:147-150.
604. Guttman C. NSAIDs vital tool for optimized cataract outcomes. Ophthalmology Times. 2005 April;30:8:1,42.
605. Guttman C. Twice-daily NSAID relieves post-cataract inflammation. Ophthalmology Times. 2005 May;30:9:1,8.
606. Hamris WS, Taylor BC, Winslow RL. Cystoid macular edema following intraocular lens implantation. Ophthalmic Surg 1977;8:134-137.
607. Harbour JW, Smiddy WE, Rubsamen PE, et al. Pars plana vitrectomy for chronic pseudophakic cystoid macular edema. AmJ Ophthalmol 1995;120:302-307.

BIBLIOGRAPHY: Clinical Retina

608. Heier JS, Topping TM, Baumann W, et al. Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. *Ophthalmology*. 2000;107:2034-2039.
609. Heimann, H et al, Atlas of Fundus Angiography, Stuggart: Thieme, 2006.
610. Herbstein K, Murchland JB. Retinal vascular changes after treatment with hyperbaric oxygen. *Med J Australia* 1984;140:728-729.
611. Hitchings RA, Chisholm IH, Bird AC. Aphakic macular edema: Incidence and pathogenesis. *Invest Ophthalmol Vis Sci* 1975;14:68-72.
612. Hitchings RA, Chisholm IH. Incidence of aphakic cystoid macular edema: A prospective study. *BrJ Ophthalmol* 1975;59:444-450.
613. Hitchings RA. Aphakic macular Oedema: a two-year follow-up study. *Br J Ophthalmol* 1977;61:628-630.
614. Ho PC, Tolentino FI. The role of vitreous in aphakic cystoid macular edema: A review. *Am Intraoc Implant SocJ* 1982;8:258-264.
615. Hogan MJ, Kimura SJ, Thygeson P. Signs and symptoms of uveitis. *Am J Ophthalmol* 1959;47:155-170.
616. Holekamp NM: Treatment of pseudophakic CME. *Ocul Immunol Inflamm* 1998 Jun; 6(2): 121-3.
617. Hollwich F, Jacobi K, Kuchle HJ, et al. Zur Prophylaxe des zystoiden maculaedems mit Indomethacin-Augentropfen. *Klin Monatsbl Augenheilkd* 1983;183:477-478.
618. Hoyt CS, Nickel B. Aphakic cystoid macular edema. Occurrence in infants and children after transpupillary lensectomy and anterior vitrectomy. *Arch Ophthalmol* 1982;100:746-749.
619. Hykin PG, Gardner ID, Corbett MC, et al. Primary or secondary anterior chamber lens implantation after extracapsular cataract surgery and vitreous loss. *Eye* 1991;5:694-698.
620. Ibanez HE, Leshner MP, Singerman LJ, et al. Prospective evaluation of the effect of pseudophakic cystoid macular edema on contrast sensitivity. *Arch Ophthalmol*
621. Irvine AR, Bresky R, Crowder BM, et al. Macular edema after cataract extraction. *Ann Ophthalmol* 1971;3:1234-1240.
622. Irvine AR. Cystoid macular edema, Irvine-Gass syndrome. In: Fraunfelder FT, Roy FH, eds. *Current Ocular Therapy*. Philadelphia: Saunders; 1980:517-519.
623. Irvine AR. Cystoid maculopathy. *Surv Ophthalmol* 1979;21:1-17.
624. Irvine SR. A newly defined vitreous syndrome following cataract surgery. *Am J Ophthalmol* 1953;36:599-619.
625. Irvine SR: A newly defined vitreous syndrome following cataract surgery interpreted according to recent concepts of the structure of the vitreous. *American Journal of Ophthalmology* 1953; 36: 599-619.
626. Italian Diclofenac Study Group: Efficacy of diclofenac eyedrops in preventing postoperative inflammation and long-term cystoid macular edema. Italian Diclofenac Study Group. *J Cataract Refract Surg* 1997 Oct; 23(8): 1183-9.
627. Jacobson DR, Dellaporta A. Natural history of cystoid macular edema after cataract extraction. *Amj Ophthalmol* 1974;77:445-447.
628. Jaffe NS, Clayman HM, Jaffe MS. Cystoid macular edema after intracapsular and extracapsular cataract extraction with and without an intraocular lens. *Ophthalmology* 1982;89:25-29.

BIBLIOGRAPHY: Clinical Retina

629. Jaffe NS, Eichenbaum DM, Clayman HM, et al. A comparison of 500 Binkhorst implants with 500 routine intracapsular cataract extractions. *Am J Ophthalmol* 1978;85:24-27.
630. Jaffe NS, Luscombe SM, Clayman HM, et al. A fluorescein angiographic study of cystoid macular edema. *AmJ Ophthalmol* 1981;92:775-777.
631. Jaffe NS. Intraocular lenses: Secondary membranes; cystoid macular edema. *Trans Am Acad Ophthalmol Otolaryngol* 1978;85:157-163.
632. Jaffe NS. Macular retinopathy after separation of vitreoretinal adherence. *Arc Ophthalmol* 1967;78:585-591.
633. Jaffe NS: Results of intraocular lens implant surgery: The Third Binkhorst Medical Lecture. *AmJ Ophthalmol* 1978;185:13-23.
634. Jampol LM, Sanders DR, Kraff MC. Prophylaxis and therapy of aphakic cystoid macular edema. *Surv Ophthalmol* 1984;28:535-539.
635. Jampol LM. Aphakic cystoid macular edema: A hypothesis. *Arch Ophthalmol* 1985;103:1134-1135.
636. Jampol LM. Cystoid macular edema following cataract surgery. *Arch Ophthalmol* 1988; 106:894-895.
637. Jampol LM. Pharmacologic therapy of aphakic and pseudophakic cystoid macular edema-1985 update. *Ophthalmology* 1985;92:807-810.
638. Jampol LM. Pharmacologic therapy of aphakic cystoid macular edema. *Ophthalmology* 1982;80:891-897.
639. Johansen J, Theodorsen FP, Corydon L. Visual outcome following complicated extracapsular cataract extraction. *J Cataract Refract Surg* 1992;18:577-581.
640. Junge J. Cystoid macular edema associated with PVP coating of an intraocular lens. *Am Intraoc Implant Soc J* 1980;6: 28-29.
641. Katzen LE, Fleischman JA, Trokel S. YAG laser treatment of cystoid macular edema. *AmJ Ophthalmol* 1983;95:589-592.
642. Kim SJ, Equi R, Bressler NM. Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography. *Ophthalmology*. 2007; 114(5):881-9
643. Klein RM, Katzin HM, Yannuzzi LA. The effect of indomethacin pretreatment on aphakic cystoid macular edema. *Am J Ophthalmol* 1979;87:487-489.
644. Klein RM, Yannuzzi L. Cystoid macular edema in the first week after cataract extraction. *Am J Ophthalmol* 1976;81:614-620.
645. Kolker AE, Becker B. Epinephrine maculopathy. *Arch Ophthalmol* 1968;79:552-562.
646. Kottow M, Hendrickson P. Iris Angiography in cystoid macular edema after cataract extraction. *Arch Ophthalmol* 1975;93:487-493.
647. Kraff MC, Sanders DR, Jampol LM, et al. Effect of an ultraviolet-filtering intraocular lens on cystoid macular edema. *Ophthalmology* 1985;92:366-369.
648. Kraff MC, Sanders DR, Jampol LM, et al. Effect of primary capsulotomy with extracapsular surgery on the incidence of pseudophakic cystoid macular edema. *Am J Ophthalmol* 1984;96:166-170.
649. Kraff MC, Sanders DR, Jampol LM, et al. Factors affecting pseudophakic cystoid macular edema: Five randomized trials. *J Am Intraoc Implant Soc* 1985;11:380-385.

BIBLIOGRAPHY: Clinical Retina

650. Kraff MC, Sanders DR, Jampol LM, et al. Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. *Ophthalmology* 1982;9:885-890.
651. Kramer SG. Cystoid macular edema after aphakic penetrating keratoplasty. *Ophthalmology* 1981;88:782-787.
652. Krishnan MM, Lath NK, Govind A. Aphakic macular edema: Some observations on prevention and pathogenesis. *Ann Ophthalmol* 1985;17:253-257
653. Kunz E, Kern R, Oppong MC, et al. Macular edema following implantation of Binkhorst lenses. *Klin Monatsbl Augenheilkd* 1980;176:690-693.
654. Lakhanpal V, Schocket SS. Pseudophakic and aphakic retinal detachment mimicking cystoid macular edema. *Ophthalmology* 1987;94:785-791.
655. Lewis H, Singer TR, Hanscom TA, et al. A prospective study of cystoid macular edema after neodymium: YAG laser posterior capsulotomy. *Ophthalmology* 1987;94:478-482.
656. Lindstrom RL, Harris WS. Management of the posterior capsule following posterior chamber lens implantation. *J Am Intraoc Implant Soc* 1980;6:255-258.
657. Lippa EA, Carlson LE, Ehinger B, et al. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. *Arch Ophthalmol* 1992;110:495-499.
658. Livernois R, Sinskey RM. Complications of late capsulotomy. *Am Intraoc Implant Soc J* 1981;7:242-243.
659. Lobes LA Jr, Grand MG. Incidence of cystoid macular edema following scleral buckling procedure. *Arch Ophthalmol* 1980;98:1230-1239.
660. Machemer R. Experimental retinal detachment in the owl monkey. II. Histology of retina and pigment epithelium. *AmJ Ophthalmol* 1968;66:396-410.
661. Mackool RJ, Muldoon T, Forier A, et al. Epinephrine-induced cystoid macular edema in aphakic eyes. *Arch Ophthalmol* 1977;95:791-793.
662. Mansour AM, Green WR, Hogge C. Histopathology of commotio retinae. *Retina* 1992;12:24-28.
663. Marmion VJ. Cystoid macular edema. *Proc R Soc Med* 1976;69:905-906.
664. Marmor MF, Maack T. Enhancement of retinal adhesion and subretinal fluid absorption by acetazolamide. *Invest Ophthalmol Vis Sci* 1982;23:121-124.
665. Marmor MF. Hypothesis concerning carbonic anhydrase treatment of cystoid macular edema: Example with epiretinal membrane. *Arch Ophthalmol* 1990;108:1524-1525.
666. Martin NF, Green WR, Martin LW. Retinal phlebitis in the Irvine-Gass syndrome. *Am J Ophthalmol* 1977;83:377-386.
667. Maumenee AE. Further advances in the study of the macula. *Arch Ophthalmol* 1967;8:152-165.
668. Mc Donnell PJ, de la Cruz ZC, Green WR. Vitreous incarceration complicating cataract surgery. A light and electron microscopic study. *Ophthalmology* 1986;93:247-253.
669. McEntyre JM. A successful treatment for aphakic cystoid macular edema. *Ann Ophthalmol* 1978;10:1219-1224.
670. McGuinness R, Kennedy I, Gole G. The Prince of Wales Hospital prospective aphakic macular oedema study. *Aust J Ophthalmol* 1980;8:247-251.

BIBLIOGRAPHY: Clinical Retina

671. Menchini U, Bandello F, Brancato R, et al. Cystoid macular oedema after extracapsular cataract extraction and intraocular lens implantation in diabetic patients without retinopathy. *BrJ Ophthalmol* 1993;77:208-211.
672. Meredith TA, Kenyon KR, Singerman LJ, et al. Perifoveal vascular leakage and macular oedema after intracapsular cataract extraction. *BrJ Ophthalmol* 1976;60:765-769.
673. Meredith TA, Maumenee AE. A review of one thousand cases of intracapsular cataract extraction: I. Complications. *Ophthalmic Surg* 1979;10:32-41.
674. Meredith TA, Reeser FH, Topping TM, et al. Cystoid macular edema after retinal detachment surgery. *Ophthalmology* 1980;87:1090-1096.
675. Miami Study Group. Cystoid macular edema in aphakic and pseudophaldc eyes. *Am Ophthalmmol* 1979;88:45-48.
676. Michels RG, Green WR, Maumenee AE. Cystoid maular edema following cataract extraction (The Irvine-Gass Syndrome): A case studied clinically and histopathologically. *Ophthalmic Surg* 1971;2:217-221.
677. Michels RG, Machemer R, Mueller-Jensen K. Vitreous surgery: History and current concepts. *Ophthalmic Surg* 1974;5:13-59.
678. Michels RG, Maumenee AE. Cystoid macular edema associated with topically applied epinephrine in aphakic eyes. *AmJ Ophthalmol* 1975;80:379-388.
679. Milch FA, Yannuzzi LA. Medical and surgical treatment of aphakic cystoid macular edema. *Int Ophthalmol Clin* 1987;27:205-217.
680. Mishima S, Tanishima T, Masuda K. Pathophysiology and pharmacology of intraocular surgery. *Aust NZJ Ophthalmol* 1985;13:147-158.
681. Miyake K, Asakura M, Kobayashi H. Effect of intraocular lens fixation on the bloodaqueous barrier. *AmJ Ophthalmol* 1984;98:451-455.
682. Miyake K, Ibaraki N, Goto Y. ESCRS Binkhorst lecture 2002: pseudophakic preservative maculopathy. *J Cataract Refract Surg*. 2003;29:1800-1810.
683. Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. *Surv Ophthalmol*. 2002;47(suppl):S203-S218.
684. Miyake K, Miyake Y, Maekubo K, et al. Incidence of cystoid macular edema after retinal detachment surgery and the use of topical indomethacin. *Am J Ophthalmol* 1983;95:451-456.
685. Miyake K, Sakamura S, Miura H. Long-term follow-up study on prevention of aphakic cystoid macular oedema by topical indomethacin. *BrJ Ophthalmol* 1980;64:324-328.
686. Miyake K, Sugiyama S, Norimatsu I, et al. Aqueous prostaglandins in persistent cystoid macular edema secondary to vitreous incarceration: Effects of pars plana vitrectomy. *Jpn J Ophthalmol* 1980;24:335-345.
687. Miyake K. Indomethacin in the treatment of postoperative cystoid macular edema. *Surv Ophthalmol* 1984;28:554-568.
688. Miyake K. Prevention of cystoid macular edema after lens extraction by topical indomethacin (I): A preliminary report. *Graefes Arch Clin Exp Ophthalmol* 1977;203:81-88.
689. Miyake K. Prevention of cystoid macular edema after lens extraction by topical indomethacin (II) A controlled study of bilateral extractions. *Jpn J Ophthalmol* 1978;22:80-94.

BIBLIOGRAPHY: Clinical Retina

690. Mizuno K, Miyake K. Pre- and postoperative therapy in cataract extraction. *Ophthalmic Surg* 1987;18:143-152.
691. Morse PH, Smith VC, Pokorny JM, et al. Fundus flavimaculatus with cystoid macular changes and abnormal Stiles-Crawford effect. *Am J Ophthalmol* 1981;91:190-196.
692. Moses L. Macular edema following cataract extraction. *Am Intraoc Implant Soc J* 1978;4:17-22.
693. Newsom WA, Hood CI, Horwitz JA, et al. Cystoid macular edema: Histopathologic and angiographic correlations. *Trans Am Acad Ophthalmol Otolaryngol* 1972;76:1005-1009.
694. Newsome DA. Retinal fluorescein leakage in retinitis pigmentosa. *Am J Ophthalmol* 1986;101:354-360.
695. Nicholls JVV. Concurrence of macular edema with cataract extraction. *Arch Ophthalmol* 1956;55:595-604.
696. Nielsen PG. Macular oedema in the reattached retina. *Acta Ophthalmol* 1978;57:522-531.
697. Nikica G, Ljerka HP, Jelena P, et al. Cystoid macular edema in anterior chamber lens implantation following posterior capsule rupture. *Doc Ophthalmol* 1991;81:309-315.
698. Norton AL, Brown WJ, Carlson M, et al. Pathogenesis of aphakic macular edema. *A J Ophthalmol* 1975;80:96-101.
699. Nussenblatt RB, Kaufman SC, Palestine AG, et al. Macular thickening and visual acuity. Measurement in patients with cystoid macular edema. *Ophthalmology* 1987;94:1134-1139.
700. Obstbaum SA, Galin MA, Poole TA. Topical epinephrine and cystoid macular edema. *Ann Ophthalmol* 1976;8:455-458.
701. Obstbaum SA, Galin MA. Cystoid macular edema and ocular inflammation the corneoretinal inflammatory syndrome. *Trans Ophthalmol Soc UK* 1979;99:187-191.
702. O'Connor GR. Periocular corticosteroid injections: Uses and abuses. *Eye Ear Nose Throat Monthly* 1976;55:83-88.
703. Orzalesi N, Pierrottet C, Porta A, et al. Long-term treatment of retinitis pigmentosa with acetazolamide. *Graefes Arch Clin Exp Ophthalmol* 1993;231:254-256.
704. Pande MV, Spalton DJ, Kerr-Muir MG, Marshall J. Postoperative inflammatory response to phacoemulsification and extracapsular cataract surgery: aqueous flare and cells. *J Cataract Refract Surg.* 1996;22(suppl 1):770-774.
705. Patel A, De Bustros S, Michels RG. Pars plana vitrectomy for aphakic cystoid macular edema. *Retina* 1985;5:11-15.
706. Pearce JL. Long-term results of the Binkhorst iris clip lens in senile cataract. *Br J pseudophakia. Trans Am Acad Ophthalmol Otolaryngol* 1973;77:589-617.
707. Pendergast SD, Margherio RR, Williams GA, Cox MS Jr. Vitrectomy for chronic pseudophakic cystoid macular edema. *Am J Ophthalmol.* 1999;128:317-23.
708. Percival P. Clinical factors relating to cystoid macular edema after lens implantation. *Am Intraoc Implant Soc J* 1981;43-45.

BIBLIOGRAPHY: Clinical Retina

709. Peterson M, Yoshizumi MO, Hepler R, et al. Topical indomethacin in the treatment of chronic cystoid macular edema. *Graefes Arch Clin Exp Ophthalmol* 1992;230:401-405. *Cataract Refract Surg* 1995;21:59-63.
710. Podos SM, Becker B, Kass MA. Prostaglandin synthesis, inhibition and intraocular pressure. *Invest Ophthalmol* 1973;12:426-433.
711. Podos SM. Prostaglandins, nonsteroidal anti-inflammatory agents and eye disease. *Trans Am Ophthalmol Soc* 1976;74:637-660.
712. Poer DV, Helveston EM, Ellis FD. Aphakic cystoid macular edema in children. *Arch Ophthalmol* 1981;99:249-252.
713. Pollack A, Leiba H, Bukelman A, Oliver M. Cystoid macular oedema following cataract extraction in patients with diabetes. *Br J Ophthalmol*. 1992;76:221-224.
714. Powe NR, Schein OD, Gieser SC, et al. Synthesis of the literature on visual acuity and complications following cataract extraction with intraocular lens implantation. *Arch Ophthalmol*. 1994;112:239-252.
715. Quentin CD, Behrens-Bauman W, Gans W Prevention of cystoid macular edema with diclofenac eyedrops in intracapsular cataract extraction using the Choyce Mark IX anterior chamber lens. *Fortschr Ophthalmol* 1989;86:546-549.
716. Rahman I, Jones NP. Long-term results of cataract extraction with intraocular lens implantation in patients with uveitis. *Eye*. 2005;19:191-197.
717. Rao NA, Patchett R, Fernandez MA, et al. Treatment of experimental granulomatous uveitis by lipoxygenase and cyclo-oxygenase inhibitors. *Arch Ophthalmol* 1987;105:413-415.
718. Ray S, D'Amico DJ. Pseudophakic cystoid macular edema. *Semin Ophthalmol*. 2002;17:167-180.
719. Reese AB, Jones IS, Cooper WC. Macular changes secondary to vitreous traction. *Am J Ophthalmol* 1966;64:544-549.
720. Reese AB, Jones IS, Cooper WC. Vitreomacular traction syndrome confirmed histologically. *Am J Ophthalmol* 1970;69:975-977.
721. Reese AB. Defective central vision following successful operation for detachment of the retina. *Am J Ophthalmol* 1937;20:591-599.
722. Rho DS. Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. *J Cataract Refract Surg*. 2003;29:2378-2384.
723. Robinson D, Landers MB, Hahn DK. An anterior segment approach to aphakic cystoid macular edema. *Am J Ophthalmol* 1983;95:811-817.
724. Ruiz R, Saatci A. Visual outcome in pseudophakic eyes with clinical cystoid macular edema. *Ophthalmic Surg* 1991;22:190-193.
725. Ryan SJ. Cystoid maculopathy in phakic retinal detachment procedures. *Am J Ophthalmol* 1973;76:519-522.
726. Sakamoto A, Hangai M, Yoshimura N. Spectral-Domain Optical Coherence Tomography with Multiple B-Scan Averaging for Enhanced Imaging of Retinal Diseases. *Ophthalmology*. 2007 Nov 29
727. Sanders DR, Kraff MC, Lieberman HL, et al. Breakdown and re-establishment of the blood-aqueous barrier following implant surgery. *Arch Ophthalmol* 1982;100:588-590.

BIBLIOGRAPHY: Clinical Retina

728. Sanders DR, Kraff MC. Steroidal and nonsteroidal anti-inflammatory agents. Effects on postsurgical inflammation and blood-aqueous barrier breakdown. *Arch Ophthalmol* 1984;102:1453-1456.
729. Sanders DR, Spigelman A, Kraff C, et al. Quantitative assessment of postsurgical breakdown of the blood-aqueous barrier. *Arch Ophthalmol* 1983;101:131-133.
730. Sanders MD. Retinal vasculitis. A review. *J R Soc Med* 1979;72:908-915.
731. Schepens CL, Avila MP, Jalkh AE, et al. Role of the vitreous in cystoid macular edema. *Surv Ophthalmol* 1984;28:499-504.
732. Scheufele, T, Heier, J Pseudophakic Cystoid Macular Edema. *J Cataract Refract Surg* 2005 Aug; 31(8): 54-6.
733. Schwartz B. Physiological effects of corticosteroids on the eye. In: Schwartz B, ed. *Corticosteroids and the Eye*. Boston: Little Brown; 1980:753.
734. Scott DJ, Dollery CT, Hill DW, et al. Fluorescein studies of the retinal circulation in diabetes. *BrJ Ophthalmol* 1963;47:588-589.
735. Scott IU, Flynn HW Jr, Smiddy WE, et al. Clinical features and outcomes of pars plana vitrectomy in patients with retained lens fragments. *Ophthalmology*. 2003;110:1567-1572.
736. Sears ML. Aphakic cystoid macular edema. The pharmacology of ocular trauma. *Surv Ophthalmol* 1984; 28:525-534.
737. Sebag J, Balaz EA. Pathogenesis of cystoid macular edema: An anatomic consideration of vitreoretinal adhesions. *Surv Ophthalmol* 1984;28:493-498.
738. Severin SL. Clinical cystoid macular edema with intracapsular cataract extraction and posterior chamber lens implantation. *Ann Ophthalmol* 1983;15:631-634.
739. Severin SL. Late cystoid macular edema in pseudophakia. *Am J Ophthalmol* 1980;90:223-225.
740. Severin TD, Severin SL. Pseudophakic cystoid macular edema: A revised comparison of incidence with intracapsular and extracapsular cataract extraction. *Ophthalmic Surg* 1988;19:116-118.
741. Shammash HJF, Milkde CF. Cystoid macular edema following secondary lens implantation. *Am Intraoc Implant Soc J* 1981;7:40-42.
742. Shammash HJF, Milkie CF. Does aspirin prevent postoperative cystoid macular edema?? *Am Intraoc Implant Soc J* 1979;5:337.
743. Shepard DD. The dangers of metal-loop intraocular lenses. *Ophthalmic Surg* 1977;8:93-95.
744. Shepard DD. The fate of eyes from which intraocular lenses have been removed. *Ophthalmic Surg* 1979;10:58-60.
745. Sholiton DB, Reinhart WJ, Frank KE. Indomethacin as a means of preventing cystoid macular edema following intracapsular cataract extraction. *Am Intraoc Implant Soc J* 1979;5:137-140.
746. Singal N, Hopkins J. Pseudophakic cystoid macular edema: ketorolac alone vs ketorolac plus prednisolone. *Can J Ophthalmol*. 2004;39:245-250.
747. Solomon LD, Flurbiprofen-CME Study Group I. Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. *J Cataract Refract Surg* 1995;21:73-81. of chronic cystoid macular edema. *AmJ Ophthalmol* 1977;84:517-519.

BIBLIOGRAPHY: Clinical Retina

748. Sorr EM, Everett WG, Hurite FG. Incidence of fluorescein angiographic subclinical Cystoid Macular Edema Following Surgery macular edema following phacoemulsification of senile cataracts. *Trans Am Acad Ophthalmol* 1979;86:2013- 2018.
749. Spaide RF, Yannuzzi LA, Sisco LJ. Chronic cystoid macular edema and predictors of visual acuity. *Ophthalmic Surg* 1993;24:262-267.
750. Spaide RF, Yannuzzi LA. Cystoid macular edema after cataract surgery. *Semin Ophthalmol* 1993; 8:121-129.
751. Spallone A. Retinal fluorescein leakage in retinitis pigmentosa. *Am J Ophthalmol* 1986;102:408.
752. Spalton DJ, Bird AC, Cleary PE. Retinitis pigmentosa and retinal oedema. *Br J Ophthalmol* 1978;62:174-182.
753. Stark WJ, Maumenee AE, Fagadau W, et al. Cystoid macular edema in pseudophakia. *Surv Ophthalmol* 1984;28: 442-453.
754. Steinert RF, Puliafito CA, Kumar SR, et al. Cystoid macular edema, retinal detachment, and glaucoma after Nd:YAG laser posterior capsulotomy. *Am J Ophthalmol*. 1991;112:373-380.
755. Steinert RF, Wasson PJ. Neodymium YAG laser anterior vitreolysis for Irvine-Gass cystoid macular edema. *J Cataract Refract Surg* 1989;15:304-307.
756. Steinmetz RL, Fitzke FW, Bird AC. Treatment of cystoid macular edema with acetazolamide in a patient with serpiginous choroidopathy. *Retina* 1991;11:412-415.
757. Stern AL, Taylor DM, Dalburg LA, et al. Pseudophakic cystoid maculopathy. A study of 50 cases. *Ophthalmology* 1981;88:942-946.
758. Straatsma BR, Meyer KT, Bastek JV, et al. Posterior chamber intraocular lens implantation by ophthalmology residents. A prospective study of cataract surgery. *Ophthalmology* 1983;90:327-335.
759. Strahlman ER, Tipping R, Vogel R, et al. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt) timolol and betaxolol. *Arch Ophthalmol* 634 1995;113:1009-1016.
760. Suga K, Okuda T, Shinomiya S, et al. Anterior vitrectomy for cystoid macular edema following cataract surgery. *Jpn J Clin Ophthalmol* 1980;34:1347-1354.
761. Tanabe N, Sagae Y, Hara K. Effect of topical indomethacin treatment for cystoid macular edema after lens extraction. *Folia Ophthalmol Japonica-Bull Jpn Ophthalmol* 1983;34:178-182.
762. Tani P, Robertson DM, Langworthy A. Rhegmatogenous retinal detachment without macular involvement treated with scleral buckling. *AmJ Ophthalmol* 1980;90:503-511.
763. Tannenbaum HL, Schepens CL, Elzeneiny I, et al. Macular pucker following retinal detachment surgery. *Arch Ophthalmol* 1970;83:286-293.
764. Taylor DM, Sachs SW, Stem AL. Aphakic cystoid macular edema. Longterm clinical observations. *Surv Ophthalmol* 1984;28:437-441.
765. Tennant JL. Is cystoid macular edema reversible by oral indomethacin, yes or no? In: Emery JM and Paton D, eds. *Current Concepts in Cataract Surgery. Selected Proceedings of the Fourth Biennial Cataract Surgical Congress*. St Louis: Mosby; 1976:310-312.

BIBLIOGRAPHY: Clinical Retina

766. Thomas JV, Gragoudas ES, Blair NP, et al. Correlation of epinephrine use and macular edema in aphakic glaucomatous eyes. *Arch Ophthalmol* 1978;96:625-628.
767. Thompson JT, Glaser BM. Role of lensectomy and posterior capsule in movement of tracers from vitreous to aqueous. *Arch Ophthalmol* 1985;103:420-421.
768. Tolentino FI, Schepens CL. Edema of posterior pole after cataract extraction-A biomicroscopic study. *Arch Ophthalmol* 1965;74:781-786.
769. Tripathi RC, Fekrat S, Tripathi BJ, et al. A direct correlation of the resolution of pseudophakic cystoid macular edema with acetazolamide therapy. *Ann Ophthalmol* 1991;23:127-129.
770. Tso MOM, Shih C. Experimental macular edema after lens extraction. *Invest Ophthalmol Vis Sci* 1977;16:381-392.
771. Tsukahara S, Kohda N. The effects of prostaglandins on the blood-ocular barrier: II Blood-retinal barrier. *Acta Soc OphthalmolJpn* 1977;81:193-198.
772. Ursell PG, Spalton DJ, Whitcup SM, Nussenblatt RB. Cystoid macular edema after phacoemulsification: relationship to blood-aqueous barrier damage and visual acuity. *J Cataract Refract Surg*. 1999;25:1492-1497.
773. Van Haeringen NJ, Glasius E, Oosterhuis JA, et al. Drug prevention of blood-aqueous barrier disruption. *Ophthalmic Res* 1983;15:180-184.
774. Vannas A. Fluorescein angiography of the vessels of the iris in pseudoexfoliation of the lens capsule, capsular glaucoma and some other forms of glaucoma. *Acta Ophthalmol Suppl* 1969;105:28-75.
775. Vogt A. Ophthalmoskopische Untersuchungen der Macula Lutea im rotfreien Licht. *Klin Monatsbl Augenheilkd* 921; 66:321-334.
776. Vogt A. Weitere ophthalmoskopische Beobachtungen in Rotfreiem Licht. *Echte*
777. Waitzman MB. Topical indomethacin in treatment and prevention of intraocular inflammation-with special reference to lens extraction and cystoid macular edema. *Ann Ophthalmol* 1979;11:489-491.
778. Ward DA. Comparative blood-aqueous barrier stabilizing effect of topical flurbiprofen, diclofenac, tolmetin and suprofen. *Invest Ophthalmol Vis Sci* 1994;35:1885.
779. Welch RB, Cooper JC. Macular edema, papilledema and optic atrophy after cataract extraction. *Arch Ophthalmol* 1958;59:665-675.
780. West CE, Fitzgerald CR, Sewell JH. Cystoid macular edema following aphakic keratoplasty. *AmJ Ophthalmol* 1973;75:77-81.
781. Wetzig PC, Thatcher DB, Christiansen JM. The intracapsular versus the extracapsular cataract technique in relationship to retinal problems. *Trans Am Ophthalmol Soc* 1979;77:339-347.
782. Wilkerson M, Cyrlin M, Lippa EA, et al. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. *Arch Ophthalmol* 1993;111:1343-1350.
783. Wilkinson CP. A long-term follow-up study of cystoid macular edema in aphakic and pseudophakic eyes. *Trans Am Ophthalmol Soc* 1981;79:810-839.
784. Winslow RL, Taylor BC, Harris WS. A one-year follow-up of cystoid macular edema following intraocular lens implantation. *Trans Am Acad Ophthalmol Otolaryngol* 1978;85:190-196.

BIBLIOGRAPHY: Clinical Retina

785. Winslow RL, Taylor BC. Retinal complications following YAG laser capsulotomy. *Ophthalmology*. 1985;92:785-789.
786. Wolter JR. The histopathology of cystoid macular edema. *Graefes Arch Klin Exp Ophthalmol* 1981;216:85-101.
787. Wright PL, Wilkinson CP, Balyeat HD, et al. Angiographic cystoid macular edema after posterior chamber lens implantation. *Arch Ophthalmol* 1988;106:740-744.
788. Yamaaki H, Hendrikse F, Deutman AF. Iris angiography after cataract extraction and the effect of indomethacin eye drops. *Ophthalmologica* 1984;188:82-86.
789. Yamada E. Some structural features of the fovea centralis in the human retina. *Arch Ophthalmol* 1969;82:151-159.
790. Yannuzzi LA, Wallyn RH. Cystoid macular edema. A controlled treatment study utilizing indomethacin. In: Emery JM, Paton D, eds. *Current Concepts in Cataract Surgery. Selected Proceedings of the Fourth Biannual Cataract Surgical Congress*. St Louis: Mosby; 1976:313-316.
791. Yannuzzi LA. A perspective on the treatment of aphakic cystoid macular edema. *Surv Ophthalmol* 1984;28:540-553.
792. Yanoff M, Fine BS, Brucker AJ, et al. Pathology of human cystoid macular edema. *Surv Ophthalmol* 1984;28:505-511.
793. Yoshinao M, Hidetoshi N. Fluorophotometry of the intraocular barrier in aphakia and pseudophakia. *Cataract* 1984;25:12-15.
794. Yoshioka H, Kawashima K. Macular edema following cataract extraction. *Acta Soc Ophthalmol Jpn* 1971;75:2269-2273.
795. Yoshioka H, Sugita T, Kawashima K. Cystoid macular edema after cataract or retinal detachment surgery and contusion. *Acta Soc Ophthalmol Jpn* 1971;75:1027-1033.
796. Young PW, Shea M. Pars plana vitrectomy in the management of the Irvine-Gass syndrome. *Can J Ophthalmol* 1980;15:172-175.
797. Zweng HC, Little HL, Peabody RR. Laser photocoagulation of macular lesions. *Tran Am Acad Ophthalmol Otolaryngol* 1968;72:377-388.